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Vav1 and the Tec family kinase Itk act in similar T cell activation pathways. Both molecules inte-
ract with members of the Cbl family of E3 ubiquitin ligases, and signaling defects in Vav1–/– T cells 
are rescued upon deletion of Cbl-b. During my PhD study I investigated the relation between Itk 
and Cbl-b or Vav1 by generating Itk/Cbl-b and Itk/Vav1 double-deficient mice. Deletion of Cbl-b 
in Itk–/– CD4+ T cells restored proliferation and partially IL-2 production, and led also to a variable 
rescue of IL-4 production. Thus, Itk and Vav1 act mechanistically similar in peripheral T cells, 
since the defects in Itk–/–  T cells, like in Vav1–/– T cells, are rescued if cells are released from the 
negative regulation mediated by Cbl-b. In addition, only few peripheral CD4+ and CD8+ T cells 
were present in Vav1–/–Itk–/–mice due to severely impaired thymocyte differentiation.  
Vav1–/–Itk–/– thymocyte numbers were strongly reduced compared to wildtype, Itk–/–or Vav1–/– 
mice, and DP thymocytes displayed increased cell death and impaired positive selection. There-
fore, our data also reveal that the combined activity of Vav1 and Itk is required for proper T cell 
development and the generation of the peripheral T cell pool. 
Itk has also been shown to be essential for the development of conventional T cells. As a 
consequence, Itk–/– mice have a relative increase in Memory phenotype (MP) T cells with innate 
characteristics. We could show in an Affymetrix gene chip approach that the transcription factor 
PLZF is up-regulated in the Itk–/– T cell population. Immunoblot analysis revealed that PLZF was 
primarily expressed in the CD4+CD44hi population both in wildtype and Itk–/– T cells. This observa-
tion suggested a link between PLZF expression and MP CD4+ T cells. Transgenic expression of 
PLZF during T cell development and in CD4+ and CD8+ T cells induced a T cell intrinsic program 
leading to an increase in peripheral CD44hi MP CD4+ and CD8+ T cells and a corresponding de-
crease of naïve CD44lo T cells. The MP CD4+ and CD8+ T cells produced IFNγ upon 
PMA/ionomycin stimulation, thus showing innate-like function. Changes in the naïve versus 
memory-like subset distribution were already evident in SP thymocytes, indicating PLZF-induced 
T cell developmental alterations. In addition, CD1d-restricted NKT cells in PLZF transgenic mice 
showed impaired development and were severely reduced in the periphery. Finally, after anti-
CD3/CD28 stimulation, CD4+ transgenic T cells showed reduced IL-2 and IFNγ production but 
increased IL-4 secretion due to enhanced IL-4 production of the CD44hiCD62L+ subset. Our data 
indicate that PLZF is a novel transcriptional regulator of the development of CD44hi MP T cells 





Aus bisher publizierten Studien war bekannt, dass der Guanosinnukleotid-Austauschfaktor Vav1 
und die Tyrosin-Kinase Itk, ein Mitglied der Familie der Tec Kinasen, in ähnlichen T-Zell Aktivie-
rungs-Signalwegen agieren. Beide Proteine interagieren mit Cbl-b, einer E3-Ubiquitin-Ligase. 
Während meiner Doktorarbeit untersuchte ich das genetische Zusammenspiel dieser drei Pro-
teine mit Hilfe von Itk/Vav1 sowie Itk/Cbl-b Doppel-knockout Mäusen. Die Abwesenheit von Cbl-
b in Itk–/– CD4+ T-Zellen führte wieder zu einer normalen T-Zell-Proliferation und IL-2 Produktion 
nach T-Zell-Rezeptor-Aktivierung, während die Produktion von IL-4 nur teilweise wieder erlangt 
werden konnte. Diese „Rettung“ des Itk-Defekts in Abwesenheit von Cbl-b ist sehr ähnlich der 
Beobachtung, dass der Defekt von Vav1-defizienten T-Zellen ebenfalls durch die Entfernung von 
Cbl-b aufgehoben werden konnte. Unsere Studien zeigen daher auf genetischer Ebene, dass Itk- 
und Vav1-abhängige Signalwege in T-Zellen mechanistisch ähnlich agieren bzw. durch Cbl-b ähn-
lich reguliert werden. Die Analyse von Vav1–/–Itk–/– Mäusen hat ergeben, dass die Entstehung 
von T-Zellen in Abwesenheit von Itk und Vav1 stark beeinträchtig war und nur sehr wenige CD4+ 
und CD8+ T-Zellen vorhanden waren. Wir konnten zeigen, dass diese starke Reduktion durch 
einen erhöhten Zelltod von Thymozyten und einer Blockade der positiven Selektion während der 
Thymozytenreifung hervorgerufen worden ist. Unsere Daten zeigen daher zum ersten Mal, dass 
die kombinierte Aktivität von Vav1 und Itk für die Entstehung von T-Zellen und die Generierung 
des peripheren T-Zell-Pools notwendig ist. 
Studien haben gezeigt, dass Itk für die Entstehung der sogenannten „konventionellen“ T-
Zellen wichtig ist. In Abwesenheit dieser Tyrosin-Kinase ist deshalb eine spezielle Population von 
CD44hi Memory-Phänotyp (MP) T-Zellen relativ erhöht. Mittels einer Affymetrix gene chip Analy-
se konnten wir zeigen, dass der Transkriptionsfaktor PLZF in Itk knockout T-Zellen hochreguliert 
ist. Die erhöhte Expression dieses Faktors wurde auf die CD44hi CD4+ T-Zellen zurückgeführt. T-
Zellspezifische transgene Überexpression von PLZF in Mäusen induzierte ein T-Zell-intrinsisches 
Programm, welches zur Entstehung dieser CD44hi T-Zellen führte. Die entstandenen MP CD4+ 
und CD8+ T-Zellen produzierten IFNγ nach Stimulierung mit PMA und Ionomycin, was eine cha-
rakteristische Eigenschaft von den sogenannten „innate-like“ T-Zellen ist. Die Veränderung der 
Verteilung von naiven versus MP T-Zellen in den PLZF transgenen Mäusen konnte schon wäh-
rend der T-Zell-Entwicklung beobachtet werden. Weiter zeigten die transgenen Mäuse, aufgrund 
eines Entwicklungsdefektes, eine stark verringerte Anzahl von CD1d-abhängigen NKT-Zellen in 
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Thymus und Milz. Zudem konnten wir zeigen, dass die transgenen CD4+ T-Zellen nach T-Zell-
Rezeptor-Stimulierung reduzierte Mengen an IL-2 und IFNγ, jedoch erhöhte Mengen von IL-4 
produzierten. Die Daten des zweiten Teils meiner Doktorarbeit weisen darauf hin, dass PLZF ein 
wichtiger Transkriptionsfaktor für die Reifung und Funktion von CD44hi MP T-Zellen mit „innate-





1.1 T lymphocytes 
Mature T lymphocytes (T cells) circulate through the peripheral lymphoid tissues where they 
are important mediators of an adaptive immune response. T cells recognize their corresponding 
antigens through their surface receptors (T cell receptor, TCR) presented in the context of major 
histocompatibility complex (MHC) molecules by an antigen presenting cell (APC). The majority of 
T cells express αβ-T cell receptor complexes on their surface, composed of α- and β-chains re-
sponsible for the recognition of antigen, and the CD3γ-, CD3δ- and CD3ε-chains which mediate 
signal transduction. In addition a second signal is provided by simultaneous binding of the MHC 
molecules on the APC to the coreceptors (CD4 or CD8) on the T cell, which is necessary for prop-
er T cell activation. The Expression of the coreceptor defines two functionally distinct popula-
tions of peripheral T cells. Most CD4+ T cells are MHC class II restricted and function as helper T 
cells, whereas CD8+ T cells are mainly MHC class I restricted and acquire a cytotoxic phenotype. 
Upon activation, helper T cells secrete cytokines to stimulate effector cells of the immune sys-
tem, while activated cytotoxic T cells destroy their target cells via secretion of cytotoxic compo-
nents. 
1.1.1 T cell development 
T cells develop from committed lymphoid progenitors that arise in the bone marrow and mi-
grate to the organ of T cell development – the thymus. The thymus provides a special environ-
ment which leads to proliferation of the lymphoid precursors and to the commitment into the T 
cell lineage.  
Development of the conventional αβ-TCR lineage: The most immature thymocytes express 
neither CD4 nor CD8 and are therefore termed double-negative (DN) cells and can be divided 
into different maturation stages due to their expression of surface molecules (1). Stage 1 cells 
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(DN1) express CD44 an adhesion molecule and are negative for CD25 (α-chain of the IL-2 recep-
tor). At stage 2, when the cells up-regulate CD25 (DN2 cells) they begin to rearrange the β-chain 
locus and progress into stage 3, where they become CD44low (DN3 cells). The DN3 stage cells get 
arrested until they have productively rearranged their β-chain locus. If the produced β-chain 
pairs with the pre-α-chain (pTα) it forms the pre-T cell receptor (pre-TCR). Cell surface expres-
sion of the pre-TCR together with CD3 signals the termination of β-chain gene rearrangement 
(termed β-selection) and leads to excessive proliferation, resulting in the loss of CD25 (DN4-
stage) . Eventually when the DN4 cells cease to proliferate, they express CD4 and CD8 and are 
therefore termed double positive cells (DP) (2). This small DP cells then begin with the rear-
rangement of the α-chain locus. After a successful rearrangement, the DP cells express low levels 
of a αβ-TCR and the associated CD3 complex which is necessary for positive selection. Positive 
selection prevents the DP cells from programmed cell death (apoptosis) and leads to their matu-
ration into CD4+ single-positive (CD4 SP) or CD8+ single-positive (CD8 SP) cells. Only very few of 
the TCRs generated will be able to recognize self-peptide/self-MHC complexes and thus are se-
lected for survival in the thymus. These positively selected cells will show self-MHC restricted 
responses to foreign antigens. T cells whose TCR recognizes self-peptide/self-MHC complexes 
too strongly will be negatively selected and undergo apoptosis to prevent autoimmunity, since 
they would be potentially self-reactive (3).  
 
Fig.1 shows a simplified scheme of the conventional T cell development in the thymus from DN-stages on 
until mature CD4+ or CD8+ single-positive T cells. 
Development of non-conventional αβ-TCR lineages: CD4+ CD8+ thymocytes give rise to not 
only the conventional T cell lineage, but also to the so called “non-conventional” or “innate” T 
cells. The best studied examples of these non-conventional T cell lineages are the CD1d specific 
natural killer T (NKT) cells. These cells are either CD4+ or CD4- CD8- (4). NKT cell selection requires 
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their ligation to glycolipid antigens presented by CD1d on DP cortical thymocytes. Type I NKT 
cells which are also termed invariant NKT cells (iNKT cells) show a very restricted T cell receptor 
repertoire. In mice they express an invariant Vα14-Jα18 chain in combination with certain TCR β-
chains (Vβ8.2, Vβ7 or Vβ2) (5, 6). Therefore iNKT cells are a population consisting of some clones 
that express different combinations of these TCRs mentioned above, but still they uniformly 
react to CD1d tetramers loaded with the glycoshpingolipid antigen α-galactosylseramide, allow-
ing the iNKT cell population to be tracked as a whole. After selection, iNKT cell precursors under-
go a series of differentiation steps characterized by the expression of defined surface markers. 
The most immature iNKT cells are HSAhigh followed by a HSAlow stage, the so called stage 1 where 
they do not express CD44 or NK1.1. When iNKT cells progress into stage 2, they up regulate 
CD44, and in a final maturation step they start to express NK1.1 (stage 3) (7). Part of the imma-
ture iNKT cells at stage 2 already can leave the thymus and show final maturation in the peri-
phery. However some very mature stage 3 iNKT cells reside in the thymus, the reason for this 
phenomenon is not clear to date. If mature iNKT cells in the periphery encounter their antigen 
they are capable to show immediate effector function like the production of IL-4 and IFN-γ. The 
defined function of iNKT cells in the immune system still needs to be further investigated but 
there is clear evidence that iNKT cells are able to enhance microbial immunity and tumor rejec-
tion, but also promote tolerance and suppress autoimmune diseases (8).  
An additional innate T cell lineage develops from a double-positive progenitor that is CD8+ as 
a mature cell. These non-conventional CD8+ T cells express a TCR specific for non-classical MHC 
class Ib molecules, like H2-M3 (histocompatibility 2, M region locus 3), Qa-1 (H2-T23) and MR1 
(MHC class I related) (4). 
 
Fig.2 is showing the T cell lineages which develop from the DP progenitor cells in the thymus, like conven-
tional naïve CD4+ and CD8+ T cells, CD4+ innate T cells (e.g. NKT cells) and CD8+ innate T cells. 
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The two main differences between conventional and non-conventional T cell development 
are the differences in the TCR repertoire and the dependence on interactions with epithelial 
cells versus bone marrow derived cells, such as thymocytes. In contrast to conventional naïve T 
cells, which undergo positive selection following moderate affinity interactions with classical 
MHC molecules expressed on thymic epithelial cells, non-conventional T cells are selected by 
TCR interactions with non-classical MHC molecules expressed on thymocytes (4). DP thymocytes 
provide signals to the selected T cell which are not provided by thymic epithelial cells, therefore 
contributing to the innate T cell development. Homotypic interactions across DP cell-DP cell con-
tacts generate these second signal mediated by engagement of hemophilic receptors of mem-
bers of the signaling lymphocytic activation molecule (SLAM) family (9). 
 
Fig.3 shows the differences between conventional versus non-conventional T cell development (modified 
from Berg L. Nature Reviews Immunology 2007). Conventional T cells are selected in the thymus by thymic 
epithelial cells on MHC class I or II, while innate T cells are selected via interaction with non classical MHC 
molecules presented on bone marrow derived thymocytes. 
Innate T cells share some characteristics as the expression of defined surface markers like 
CD44hi, CD122hi and some express NK1.1, as well as they all show immediate effector functions 
(cytokine production) and some are dependent on IL-15 for their survival (e.g. NKT cells). In gen-
eral it is thought that these innate T cells may serve as an important so called first line of de-
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fense against certain bacteria and may therefore build kind of a bridge between the innate and 
adaptive immunity (10). 
Development of the γδ-TCR lineage: During the double-negative stages in the thymus, DN3-
stage thymocytes not only rearrange the β-chains, but simultaneously also the γ- and δ-chains. If 
a complete γδ-TCR is formed before a successful β-chain rearrangement has led to the produc-
tion of a pre-TCR, the thymocytes already receive a signal through the γδ-TCR. This signal leads 
to the cessation of the β-chain rearrangement and the cell has been committed to the γδ-TCR 
lineage. Mature γδ-T cells mainly reside in the gut and strikingly do not seem to require antigen 
processing and MHC presentation of peptide epitopes although some recognize MHC class IB 
molecules. Thus γδ-T cells also seem to play a role in bridging the innate and adaptive immune 
response like the non-conventional αβ-T cells (11). 
1.1.2 Transcription factors involved in T cell development 
To make choices between T-lineages transcription factors and signaling molecules are used 
throughout the T cell development to establish T cell identity and sub specializations. These mo-
lecules include Notch proteins and their transcriptional effector RBPSuh(CSL);GATA-3; the bHLH 
factors E2A and HEB and their antagonists Id2 and Id3;Runx1 and Runx3; and also members of 
the Ikaros family. The individual functions these factors perform are stage-specific, disconti-
nuous and even subject to alternation between activating and inhibitory effects from one stage 
to the next (for review see(12)). 
BTB domain-containing zinc finger proteins 
Several members of the BTB (bric-a-brac broad complex) domain-containing family of zinc 
finger proteins (BTB-ZF) have been described to be important for the development and function 
of T lymphocytes: MAZR, Th-POK (also named cKrox), Bcl6, BAZF (Bcl6b), ROG (PLZP /FAZF) and 
PLZF. MAZR was shown to be a repressor of CD8 expression in early thymocyte development 
(13), while a more recent study in our laboratory could show a role for MAZR in CD4/CD8 cell 
fate decisions during thymocyte development (Shinya Sakaguchi, unpublished data). cKrox also 
known as Th-POK is an important master regulator of helper lineage commitment (14). In con-
trast Bcl6 seems to play a more important role in regulating T cell function rather than T cell 
development. Studies have implicated Bcl-6 in the repression of GATA-3, therefore negatively 
regulating the development of TH2 cells (15). Another study could show a function for Bcl-6 in 
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the generation of CD8+ memory T cells, especially for the development of the so called central 
memory subset (16). BAZF/Bcl6b a quite close relative to Bcl-6 seems to be important in naïve 
CD4+ T cells. BAZF/Bcl6b deficient CD4+ T cells show impaired proliferation and IL-2 production 
upon T cell receptor triggering (17). However this was not observed by another group which 
independently generated Bcl6b knock-out mice. This additional studies rather could show a 
function for Bcl6b in the generation of a secondary response of CD8+ memory T cells (18). Stu-
dies with ROG/PLZP deficient mice implicated this factor to be a negative regulator of T cell proli-
feration and IL-2 production upon engagement of the T cell receptor (19). This proteins contain 
an N-terminal BTB-POZ domain which is necessary for their interaction with e.g. HDAC1 (histone 
deacetylase 1), mSin3a (Swi independent 3A), SMRT (silencing mediator of retinoid and thyroid 
hormone receptors) and NCoR (nuclear Corepressor), thereby mediating transcriptional repres-
sion. The C-terminal Zinc-finger domains are required for DNA binding (for review see (20)). 
PLZF (Promyelocytic Leukemia Zinc Finger) 
Another member of the BTB-ZF family of transcription factors PLZF became famous as a fu-
sion protein with the retinoic acid receptor α (RARα) protein. This PLZF-RARα fusion protein 
leads to acute promyelocytic leukemia (APL) (for review see(21)). Additional studies could show 
the importance of PLZF for limb development and spermatogenesis (22-25). Two recent studies 
implicated PLZF in NKT cell development and function. These studies which were performed 
using PLZF deficient mice have shown that in the absence of PLZF very few NKT cells develop and 
that the remaining NKT cells show impaired effector functions and do not acquire the phenotype 
and innate-like characteristics usually associated with iNKT cells (26, 27). An additional study 
could show that enforced expression of PLZF can drive effector functions on CD4+ T cells (27). 
 
Fig.4 shows a schematic map of the BTB-ZF protein PLZF. The protein consists of an N-terminal BTB do-
main and 9 C-terminal Zinc finger domains. The protein domain structure is commonly shared within the 
BTB-ZF family of transcription factors. 
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1.1.3 T cell homeostasis 
Mature single-positive thymocytes emigrate from the thymus to the peripheral organs of the 
immune system- the lymph nodes, spleen and the mucosal lymphoid tissues. In the absence of 
an infection the size and composition of the peripheral T cell pool has to be tightly controlled. 
Peripheral T cells should be kept constant in numbers and should contain diverse but potentially 
functional T cell receptors. This regulatory process is known as T cell homeostasis. 
It has been shown that the cytokine interleukin-7 (IL-7) plays an important role in the surviv-
al of peripheral T cells, thus a limiting amount of this cytokine keeps the T cell pool constant in 
size. Transfers of naïve T cells into mice which do not contain a T cell pool (e.g. RAG knock-out 
mice, a so called “empty host”) have shown that these transferred naïve cells proliferate and 
acquire a memory phenotype. This could be explained by the plethora of survival factors in this 
“empty organs” and a reduced competition for these factors. Furthermore there seems to be a 
requirement for interactions with self-peptide/self MHC-complexes, which leads mature naïve T 
cells to undergo infrequent cell divisions. This slight increase in T cell numbers is balanced by loss 
of T cells most likely among daughter cells of the dividing naïve cells (28). 
1.1.4 T cell receptor signaling 
Signal transduction by the T cell receptor is linking antigen recognition with a functional re-
sponse of the T cell. The recognition of antigen initiates a sequence of biochemical signals in T 
cells that result in proliferation and lead to the expression of various genes. Not only the signal 
through the TCR (signal 1) which is mediated by the binding of the foreign-peptide/self MHC 
complex, is important to fully activate a naïve T cell. Effective activation also requires a co-
stimulatory signal (signal 2) transmitted through the CD28 coreceptor, to be delivered by the 
same antigen presenting cell (APC) which leads to IL-2 production and increased survival of the T 
cell. If a T cell recognizes antigen in the absence of co-stimulatory molecules, it receives signal 1 
alone and is inactivated to prevent potentially self reactivity and allows self antigens expressed 
on tissue cells to induce tolerance in the peripheral T cell population. Once the cells have diffe-
rentiated into effector cells, any encounter of the antigen which the cells are responding to, 
triggers their effector actions without the need for co-stimulatory signals. 
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Tec kinases and T cell receptor signaling 
The Tec family tyrosine kinases are known to be important mediators of antigen receptor signal-
ing in lymphocytes. Three members are expressed in T cells and known to be activated in re-
sponse to T cell receptor signaling: Itk, Tec and Rlk (29). 
 
Fig.5 is showing the three members of the Tec family kinases which are expressed in T lymphocytes: Tec, 
Ikt and Rlk. Abbreviations: PH, Pleckstrin homology domain; BH, Btk homology motiv; PR, proline rich 
domain; SH3, Src homology domain 3; SH2, Src homology domain 2; KINASE, Kinase domain; CYS, cystein 
string motiv; 
Activation of the TCR receptor by antigen binding results in the activation of src family kinas-
es Lck and Fyn and the phosphorylation of ITAM motifs on the CD3 subunits. Zap-70 is bound by 
these immunoreceptor tyrosine-based activation motifs (ITAM) and activated by phosphoryla-
tion. Activated Zap-70 phosphorylates the docking protein, linker for activation of T cells (LAT). 
Several molecules bind to LAT including PLCγ1 and a trimeric complex composed of SLP-76, Vav1 
and ITK. Tec kinases are recruited to the plasma membrane through interactions of their pleck-
strin homology (PH) domain with PI(3,4,5)P3, the product of the phosphoinositid-3 kinase (PI3K). 
Therefore Tec kinases can be negatively regulated by the phosphatases PTEN and SHIP, which 
can reduce the levels of PI(3,4,5)P3 in the plasma membrane, leading to reduced recruitment of 
Tec kinases to the site of action. Rlk which does not contain a PH domain is recruited to the 
membrane by palmitoylation of the cysteine string motif and is therefore independent of PI3K. 
Two steps of tyrosine phosphorylations are needed for an activation of the Tec kinases, the 
trans-phosphorylation which is performed by the Src kinases, followed by an auto-
phosphorylation (29). In addition interactions with other signaling molecules, a so called signal-
ing complex, integrates downstream signaling events to PLCγ and the guanine nucleotide ex-
change factor Vav1.  
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 Fig.6 shows an illustration of the early events in T cell receptor signaling and the formation of the signalo-
some. Upon T cell receptor triggering Fyn activates Lck which in turn phosphorylates Itk. The Tec kinase Itk 
is recruited to the plasma membrane by PI3K which is responsible for the production of PI(3,4,5)P3. After an 
auto-phosphorylation Itk becomes part of the signaling complex, the signalosome, leading to downstream 
events necessary for T cell activation. 
Itk seems to play the most important role in T lymphocytes among the other Tec family ki-
nases Tec and Rlk. Studies with Itk-/- mice have shown the importance of Itk in T cell develop-
ment. These mice have reduced numbers of mature T cells, decreased ratios of CD4/CD8 single-
positive cells and defects in thymic positive selection (30). More recent studies have shown the 
importance of Itk in the development of conventional naïve CD8+ T cells, since Itk deficient mice 
are almost devoid of conventional CD8+ T cells. The remaining CD8+ T cells in these mice show 
innate-like characteristics and are selected on non-classical MHC class Ib molecules presented on 
bone marrow derived cells in the thymus (31-33). 
Mature Itk deficient T cells show impaired responses to TCR stimulation including prolifera-
tion, Interleukin-2 (IL-2) production and expression of effector cytokines (34, 35). Furthermore 
Itk deficient mice show defects in peripheral T cell activation and in the polarization towards a 
TH2 helper phenotype (36). 
Crosstalk between Itk and other T cell receptor signaling molecules: As already mentioned 
above the Tec kinase Itk is known to be an important molecule of the signaling complex formed 
upon TCR engagement, and therefore necessary for an efficient T cell activation. Vav1 a Dbl ho-
mology domain containing GDP/GTP guanine exchange factor that activates members of the Rho 
GTPases family (for reviews see (37, 38)) has also been shown to be necessary for a proper syn-
apse formation and efficient T cell activation. Furthermore Vav1 can interact with Itk (39), and 
9
both Vav1 and Itk are phosphorylated upon TCR stimulation (40, 41). It has been shown that the 
recruitment of Vav1 to the immunological synapse may be dependent on Itk (39, 42). More re-
cent data suggest that this recruitment could be mediated through a kinase-independent func-
tion of Itk (39, 42, 43). 
Another TCR signaling protein, the E3 ubiquitin ligase Cbl-b, which modulates activation 
thresholds in T cells and prevents the development of autoimmunity (44-46), negatively regu-
lates Vav1-mediated signaling, acting via the CD28 co-stimulatory pathway (47). The similarities 
between the biochemical and cellular defects of Itk and Vav1 deficient T cells also leads to the 
suggestion of a potential crosstalk between Itk and Cbl-b and not only between Itk and Vav1. 
1.1.5 Effector functions of T cells 
At the end of the proliferative phase of a T cell response induced by TCR engagement plus 
co-stimulatory signals, activated T cells differentiate into effector T cells. This differentiated T 
cells can synthesize the effector molecules which are required for their helper or cytotoxic func-
tions. Depending on the surrounding cytokine milieu, especially for CD4+ helper T cells, this ma-
turation can result in the development of various functionally different T cell subsets. In contrast 
CD8+ T cells always differentiate into cytotoxic T cells which kill their (mainly virus infected) tar-
get cells by expression of perforin, granzymes or fas-ligand. 
CD4+ effector T cell subsets 
TH17 and regulatory T cells: In the absence of an infection dendritic cells rather produce 
TGF-β than IL-6 leading to an induction of FOXP3 expression if a CD4+ T cell encounters antigen, 
resulting in a regulatory phenotype. Regulatory T cells (Tregs) are involved in closing down im-
mune responses after successful clearance of the antigen, and also in keeping in check responses 
that may potentially be against self. However in an early phase of an infection CD4+ T cell diffe-
rentiation shifts from a regulatory to a TH17 phenotype, due to increased access of IL-6 and low-
er amounts of TGF-β. The cytokine IL-6 leads to the expression of RORγt by the activated T cell 
and causes the production of IL-17 and IL-17f, specifically secreted by the TH17 cell subset. TH17 
cells can be maintained by IL-23 and are known to be important mediators in an inflammatory 
response but are also implicated in some autoimmune diseases. 
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TH1 and TH2 effector cells: Pathogens like intracellular bacteria or viruses activate dendritic 
cells to produce interleukin-12 (IL-12) and Natural killer cells (NK cells) to produce IFNγ. This 
causes proliferating CD4+ T cells to polarize into the TH1 subset, by activation of the JAK-STAT 
signaling pathway. IFNγ activates STAT1 which in turn induces the expression of T-bet. This tran-
scription factor binds to the locus of the IFNγ gene and turns on the expression of IFNγ. From 
then on these cells are committed into the TH1 subset and mainly produce IFNγ but also IL-2 and 
TNF-α. These TH1 helper T cell cytokines are necessary to activate macrophages, therefore con-
tributing to the clearance of intracellular pathogens. 
IL-4 can be produced by various cells (e.g. NKT cells) and is made upon infection with parasit-
ic worms and other pathogens acts on proliferating CD4+ T cells to cause them into a TH2 cell. 
The access of IL-4 leads to activation of STAT6 which promotes the expression of the transcrip-
tion factor GATA-3 in the activated T cell. GATA-3 is an activator of cytokines produced by TH2 
cells such as IL-4, but it also activates its own expression, therefore not only induces but also 
maintains the differentiation of the TH2 subset. TH2 cytokines mainly provide help to B cells by 
activating them to become antibody secreting plasma cells (48). 
 
Fig.7 (modified from Dong C., Nature Immunology Reviews 2008) is showing a simplified scheme of the 
differentiation pathways of activated CD4+ T cells into different effector T cell subsets. 
Each of the CD4+ T cell subsets produces cytokines which negatively regulate the develop-
ment or effector activity of the other subsets, thus allowing the upcoming T cell subset to domi-
nate an immune response. 
11
Memory T cells and memory-phenotype T cell populations 
Peripheral CD4+ and CD8+ T cell subsets have been traditionally divided into naïve 
CD44loCD62L+ and memory CD44hiCD62L– populations, while the surface expression phenotype 
of the latter population also resembles recently activated T cells (49, 50). In the last years it be-
came clear that the memory T cell subset is not a population consisting only of true antigen-
specific memory cells that developed in response to a foreign antigen. Rather, the memory pop-
ulation contains a variety of different T lymphocyte subsets, some may have acquired their 
memory phenotype through homeostatic proliferation, while others show immediate effector 
function and may play a role in the front-line defense against certain bacterial infections. These 
additional cells were described as memory-phenotype (MP) T lymphocytes and some subsets of 
the MP population also as innate T cells (4, 51). 
Immunological memory enables the immune system to respond more rapidly and efficiently 
to pathogens that have been encountered already previously. After an immunization the num-
ber of T cells reactive to the given antigen increases heavily as effector T cells but is going down 
again after the clearance of the pathogen. Nevertheless a small part of cells persists after an 
immune response, the so called memory T cells. These memory T cells are long-lived cells with a 
defined expression of cell surface molecules, particular responses to stimuli and the expression 
of certain genes controlling cell survival. Memory T cells for example express high levels of the 
adhesion molecule CD44 and the survival factor Bcl-2. Two types of memory T cells can derive 
from a primary immune response. 
Effector memory cells express the chemokine receptors CCR3 and CCR5, high levels of CD44, 
but are CD62L-. After re-stimulation these cells rapidly mature into effector cells and are capable 
to secrete high levels of IFN-γ, IL-4 and IL-5.  
Central memory cells express CCR7 and show a CD44hiCD62L+ surface marker expression. 
They remain in the peripheral lymphoid tissues after re-stimulation and take longer than effector 
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AIM OF THE THESIS 
The Tec kinase Itk is known to be an important mediator of T cell receptor signaling. Mice 
deficient for this tyrosine kinase show a similar phenotype as mice deficient for the guanine nuc-
leotide exchange factor Vav1 which also plays an important role upon T cell receptor triggering. 
This fact, in combination with several additional studies (for further details see part 3.1.2) and 
the observation that this two proteins interact, provided evidence that there are functional 
crosstalks between Itk and Vav1 during T cell receptor signaling. However it was still unclear 
whether the functions of Vav1 and Itk are partially redundant and whether there are crosstalks 
between these molecules not only during T cell receptor signaling in mature T cells but also dur-
ing T cell development. 
In order to investigate whether these two molecules indeed function in the same genetic 
pathways and whether there is functional redundancy between Vav1 and Itk during T cell activa-
tion, we generated Vav1/Itk double deficient mice. Since Vav1 and Itk both interact with mem-
bers of the Cbl family of E3 ubiquitin ligases, and signaling defects in Vav1–/– T cells are rescued 
upon deletion of Cbl-b, we further wanted to investigate the relation between Itk and Cbl-b by 
generating Itk/Cbl-b double-deficient mice. 
In addition we wanted to determine a potential role of the transcription factor PLZF (pro-
myelocytic leukemia zinc finger) in the T cell lineage since this protein was identified in an Af-
fymetrix microarray to be up-regulated in Itk deficient T cells. Itk–/– mice have a T cell memory 
phenotype (MP), and we could show that the increase in the expression of PLZF in Itk-/- T cells 
was due to a higher percentage of MP T cells. Furthermore we observed that wildtype memory 
phenotype T cells also express high levels of PLZF. These data indicated a correlation between 
PLZF and memory phenotype T cells. To gain more insight into a potential role of PLZF during T 
cell development and memory phenotype T cell function, we generated T cell specific PLZF 
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Impaired T-cell development in the absence of Vav1
and Itk
Julia Raberger1, Nicole Boucheron1, Shinya Sakaguchi1, Josef M.
Penninger2 and Wilfried Ellmeier1
1 Division of Immunobiology, Institute of Immunology, Center for Physiology, Pathophysiology
and Immunology, Medical University of Vienna, Vienna, Austria
2 Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
Vav1 and the Tec family kinase Itk act in similar T-cell activation pathways. Both
molecules interact with members of the Cbl family of E3 ubiquitin ligases, and
signaling defects in Vav1/ T cells are rescued upon deletion of Cbl-b. In this
study we investigate the relation between Itk and Cbl-b or Vav1 by generating Itk/Cbl-b
and Itk/Vav1 double-deﬁcient mice. Deletion of Cbl-b in Itk/ CD41 T cells restored
proliferation and partially IL-2 production, and also led to a variable rescue of IL-4
production. Thus, Itk and Vav1 act mechanistically similarly in peripheral T cells, since the
defects in Itk/ T cells, as in Vav1/ T cells, are rescued if cells are released from the
negative regulation mediated by Cbl-b. In addition, only few peripheral CD41 and CD81
T cells were present in Vav1/Itk/ mice due to severely impaired thymocyte differ-
entiation. Vav1/Itk/ thymocyte numbers were strongly reduced compared with WT,
Itk/ or Vav1/ mice, and double-positive thymocytes displayed increased cell death and
impaired positive selection. Therefore, our data also reveal that the combined activity of
Vav1 and Itk is required for proper T-cell development and the generation of the peripheral
T-cell pool.
Key words: Kinases . Knockout mice . Signal transduction . T cells
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Introduction
TCR/CD28 triggering by APC induces a signaling cascade
that leads to the activation of signaling molecules, the
reorganization of the actin cytoskeleton and the formation of
the so-called immunological synapse at the T-cell/APC inter-
phase. Together this leads to the activation of downstream
signaling components and activation of transcription factors
resulting in the induction of IL-2 expression, proliferation of the
T cells and the generation of activated effector T-cell populations,
which is important for the development of a proper adaptive
immune response [1, 2].
Molecules such as Vav1 and wasp (for review see [3]),
and also the Tec family kinase Itk, [4] have been shown to be
necessary for proper synapse formation and for efﬁcient
T-cell activation. Vav1 is a Dbl homology domain containing
GDP/GTP guanine exchange factor that activates members
of the Rho GTPases family (for reviews see [5, 6]). Genetic
studies have shown impaired development of Vav1/ thymo-
cytes indicated by reduced numbers of total thymocytes due to a
partial block at the double-negative (DN) stage. Furthermore,
the double-positive (DP) subset of Vav1/ thymocytes shows
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impaired positive selection leading to reduced numbers of
peripheral T cells, and during T-cell activation Vav1 is required
for efﬁcient TCR-mediated T-cell proliferation and cytokine
production [7–11]. Vav1 controls integrin clustering and TCR
stimulation-induced cytoskeletal reorganization required for the
formation of the immunological synapse, since Vav1/ T cells
show impaired receptor clustering upon activation [11]. The E3
ubiquitin ligase Cbl-b, which modulates activation thresholds in
T cells and prevents the development of autoimmunity [12–14],
negatively regulates Vav1-mediated receptor clustering, since the
defect in Vav1/T cells is relieved in Vav1/Cbl-b/ double-
deﬁcient T cells [15]. Remarkably, mice deﬁcient for the
protein tyrosine kinase Itk show a T-cell phenotype similar
to that of Vav1/ mice [16–18]. In addition, Itk/ CD41 T cells
are not efﬁciently polarized toward the Th2 lineage [19, 20].
Vav1 interacts with Itk [21]; both Vav1 and Itk are phosphory-
lated upon TCR stimulation [22, 23], and both can interact with
members of the Cbl gene family [24–26]. Furthermore, the
similar phenotype of Itk/ and Vav1/ T cells suggested
that Itk and Vav1 may work in similar signaling pathways
or may (partially) fulﬁll similar function (for review see [27,
28]). Vav1/ T cells display impaired activation of Itk
upon TCR stimulation; however, this effect might be
indirectly due to impaired activation of PI3K in the absence of
Vav1 [29]. Furthermore, it has been shown that the recruitment
of Vav1 to the immunological synapse may be dependent
on Itk [4, 21]. This could be regulated via Itk-dependent phos-
phorylation of linker of activated T-cells (LAT) or SH2 domain
containing leukocyte protein of 76kDa (SLP76) adaptor proteins,
which would generate docking sites for Vav1 (src homology 2
(SH2) domain-mediated), although Vav1 phosphorylation is
normal in Itk/ T cells [30]. More recent data suggest that this
recruitment could be mediated through a kinase-independent
function of Itk [4, 21, 31]. Since Itk can interact with Vav1, Itk
may be required for the recruitment of Vav1 to SLP76 [21].
Together, these data clearly suggest a functional crosstalk
between Vav1 and Itk during T-cell signaling. However, it is still
unclear whether the functions of Vav1 and Itk are partially
redundant (i.e. indicating a scaffolding function for Itk) and
whether there are crosstalks between these molecules during
T-cell development.
In this study we further investigated potential interdependences
between Itk and Cbl-b or Vav1. We investigated whether there are
mechanistic similarities in the signaling defects of Vav1/ and
Itk/ T cells. Itk/Cbl-b double-deﬁcient mice were generated to test
whether TCR signaling defects in peripheral Itk/ T cells are
rescued in the absence of Cbl-b, as observed for Vav1/ T cells
[15]. The analysis of Itk/Cbl-b/ CD41 T cells indicated, in
agreement with another study [27], restored proliferation and at
least partially rescued IL-2 production compared with Itk/ CD41
T cells. Furthermore, Itk/Cbl-b/ CD41 T cells displayed
increased Th2 polarization and IL-4 production compared with
Itk/ CD41 T cells, indicating that deletion of Cbl-b can also bypass
the requirement of Itk for the efﬁcient generation of IL-4-producing
Th2 cells. In addition, by generating Vav1/Itk double-deﬁcient mice,
we wanted to genetically determine whether Itk and Vav1 are
indeed functioning in the same genetic pathways and whether there
is functional redundancy between Vav1 and Itk during T-cell acti-
vation. Unexpectedly, Vav1/Itk/ mice showed severely reduced
numbers of peripheral T cells due to impaired thymocyte differ-
entiation. Vav1/Itk/ thymocyte numbers were strongly
reduced, the CD4/CD8 developmental proﬁle was dramatically
altered and the DP subsets displayed increased cell death compared
with WT, Itk/ or Vav1/ mice. In addition, mature CD3hi CD4
and CD8 single-positive (SP) thymocytes were absent in Vav1/
Itk/ thymi, indicating a block in positive selection. Thus, our data
reveal additional similarities between the functional defects of
Vav1/ and Itk/ T cells, and they show an essential requirement
for the combined activity of Vav1 and Itk during T-cell
development.
Results
Cbl-b deﬁciency can rescue T-cell defects of Itk/ mice
Since it has been shown that Cbl-b deﬁciency restores signaling in
Vav1-deﬁcient T cells [15], we tested whether TCR-signaling
defects in peripheral Itk/ T cells are rescued as well in the
absence of Cbl-b. Therefore, Itk/Cbl-b/ mice were generated.
Itk/ mice have reduced numbers of peripheral T cells [16], and
some CD41 T cells and the majority of CD81 T cells have an
activated/memory-like phenotype [32–35]. Similar numbers of
T cells were present in Itk/ Cbl-b/ mice compared with Itk/
mice, and Itk/ and Itk/Cbl-b/ T cells had a similar
activated/memory-like phenotype (data not shown), indicating
that the homeostasis defect of Itk-deﬁcient mice is not rescued by
deletion of Cbl-b.
To investigate whether Cbl-b rescues the proliferation defect of
Itk/ T cells, peripheral WT, Cbl-b/, Itk/ and Itk/Cbl-b/
CD41 T cells were isolated, loaded with CFSE and stimulated with
various concentrations of anti-CD3. Since both Itk/ and
Itk/Cbl-b/ mice showed a similar percentage of memory/acti-
vated CD41 T-cell phenotype, a direct comparison of total (i.e. naı¨ve
plus memory subsets) CD41 T cells was performed. As reported
previously, Cbl-b/ CD41 T cells showed hyperproliferation [12,
13], while Itk/ CD41 T cells showed reduced proliferation
compared with WT cells [16] (Fig. 1A). In contrast to Itk/ cells,
proliferation was restored in Itk/Cbl-b/ CD41 T cells (Fig. 1A).
The proliferative response to anti-CD3 plus anti-CD28 stimulation
was similar in all genotypes analyzed. Furthermore, the diminished
IL-2 production of Itk/ CD41 T cells upon costimulation [16, 32]
was partially rescued in Itk/Cbl-b/ CD41 T cells (Fig. 1B).
These data are in agreement with a recent report that in addition
also showed that Cbl-b deletion can rescue actin polarization in
Itk/ T cells [27]. Itk-deﬁcient T cells also have a Th2 polarization
defect and showed impaired production of IL-4 [19, 20]. Therefore,
we tested whether Itk/Cbl-b/ CD41 T cells are able to polarize
toward a Th2 phenotype. Since Itk/Cbl-b/ CD41 T cells showed
a tendency to produce more IL-4 compared with Itk/ CD41 T cells
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(although with variable efﬁciency, Fig. 1C), the deletion of Cbl-b
can also bypass the requirement of Itk for the efﬁcient generation of
IL-4-producing Th2 cells.
Lack of peripheral T cells in the absence of Itk and
Vav1
The above data provide further indication that Itk and
Vav1 control similar pathways in peripheral T cells, since the
functional defects of both Itk/ T cells and Vav1/ T cells can
be rescued in the absence of Cbl-b. To investigate the relation
between Itk and Vav1 more directly, and to test whether the
combined absence of Itk and Vav1 would reveal additional
phenotypes during T-cell activation compared with single-
deﬁcient mice, Vav1/ and Itk/ mice were intercrossed to
generate Vav1/Itk/ mice. As previously reported, both
Vav1/ mice [7–11] and Itk/ mice [16, 17] have reduced
numbers of peripheral T cells (Fig. 2A and B). In contrast, double-
deﬁcient mice displayed a dramatic loss of T cells both in lymph
nodes (Fig. 2A and B) and in the spleen (data not shown).
Vav1/Itk/ mice showed an approx. fourfold decrease in
peripheral T-cell numbers in lymph nodes compared with Vav1
and an approx. 20-fold reduction compared with WT mice
(Fig. 2B, lower panel). The number of B2201 B cells was slightly
increased compared with WT, Vav1/ and Itk/mice (Fig. 2B).
Impaired T-cell development in Vav1/Itk/ mice
To determine whether the reduction in the peripheral T-cell
pool in Vav1/Itk/ mice is caused by a defect during T-cell
Figure 1. Deletion of Cbl-b restored defects of Itk/ CD41 T cells. (A) Histograms showing ﬂuorescence intensity of CFSE-labeled CD41 T cells of
the indicated genotypes. T cells were activated with different concentrations of anti-CD3 (0.3 or 1.0mg/mL, left or middle panel) or with anti-CD3
plus anti-CD28 (1.0 and 3.0 mg/mL, respectively, right panel). (B) CD41 T cells were activated with anti-CD3 plus anti-CD28 or with PMA and
ionomycin for 48h and IL-2 levels in the supernatant were measured by ELISA. One representative out of three independent experiments is shown.
(C) CD41 T cells were polarized under Th2 conditions for 5 days. Dead cells were removed and puriﬁed Th2 cells were restimulated with anti-CD3
(3 mg/mL) for 12h. The IL-4 concentration in the supernatant was determined by ELISA. For each experiment, IL-4 levels of WT CD41 T cells were set
as one and the relative IL-4 levels of Cbl-b/, Itk/ and Cbl-b/Itk/ compared with WT cells were calculated. The diagram shows the results of
four independent experiments.
Eur. J. Immunol. 2008. 38: 1–13 Leukocyte signaling 3
& 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
26
Figure 2. Vav1/Itk/ mice have severely reduced numbers of peripheral T cells due to impaired thymocyte development. (A) Dot plots showing
B220 and CD3 expression on lymph node cells of the indicated genotype. Numbers next to the regions indicate the percentage of cells within the
gate. Each dot plot is representative of at least six mice. (B) Diagram showing the total numbers of T and B cells in lymph nodes of mice of the
indicated genotype. Each data point represents one mouse. (C) Dot plots showing CD4 and CD8 expression on thymocytes of the indicated
genotype. Numbers indicate the percentage of cells in the respective quadrant. Each dot plot is representative of at least six mice. (D) Diagram
showing the total thymocytes numbers (left panel), total DN numbers (middle panel) or total DP numbers (right panel) in mice of the indicated
genotype. Each data point represents one mouse.
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development, thymocytes of the various genotypes were isolated
and analyzed for the expression of CD4 and CD8. It has been
shown that Vav1/mice have an increase in the percentage of the
DN subset and reduced thymocyte cellularity [7–11], while Itk/
mice show a defect during positive selection of both CD4 and CD8
T cells [36]. In contrast to the single knockouts, Vav1/Itk/
mice displayed a severely altered CD4/CD8 expression proﬁle,
having an increase in the percentage of DN cells and a
corresponding drop in the percentage of DP thymocytes
(Fig. 2C). Thymic cellularity was further reduced (approx.
threefold) in Vav1/Itk/ mice compared with Vav1/ mice
(Fig. 2D). This was due to a reduction in the numbers of DP
thymocytes, since the number of DN cells was similar in WT,
Vav1/ and Vav1/Itk/ mice. In contrast, Itk/ mice showed
a mild increase in the numbers of DN thymocytes compared with
the other genotypes analyzed (Fig. 2D). However, the number of
TCR-gd T cells was similar in all genotypes (data not shown).
The developmental alteration in Vav1/ thymocytes is caused
by a partial block at the DN3 stage [10, 37]. To investigate
whether the developmental phenotype seen in Vav1/Itk/mice
is due to a stronger but mechanistically similar defect in compar-
ison with Vav1/ mice, the composition of the DN subset
with respect to CD44 and CD25 expression was analyzed in more
detail. While WT and Itk/ mice had a normal DN1–4 subset
distribution (Fig. 3A and B), Vav1/ showed an increase in the
DN3 subset (Fig. 3A and B), as previously reported [10, 37].
Vav1/Itk/ thymocytes had a similar increase in the DN3
subset as Vav1/ thymocytes, indicating that the severity of the
DN3 block due to Vav1 deﬁciency is not further increased in the
absence of Itk. To determine whether the diminished numbers of
DP thymocytes is caused by a reduced proliferative capacity of DN
thymocytes, BrdU labeling experiments were performed. These
experiments revealed that the BrdU incorporation was similar in
Vav1/ and in Vav1/Itk/ DN thymocytes and DP cells
and therefore indicated similar proliferation capacity (Fig. 3C).
Furthermore, the experiments showed that Vav1/ and
Vav1/Itk/ DN thymocytes, in particular DN3 and DN4
stages, showed even increased BrdU incorporation compared with
Itk/ DN cells, which behaved similar to their WT counterparts
(Fig. 3C).
Figure 3. No developmental differences between the DN subsets of Vav1/ and Vav1/Itk/ mice. (A) Dot plots showing CD44 and CD25
expression on DN thymocytes of the indicated genotype. Numbers indicate the percentage of cells in the respective quadrant. Each dot plot is
representative of at least six mice. (B) Diagram showing the percentage of DN3 thymocyte populations in mice of the indicated genotype. Each data
point represents one mouse. (C) Histograms showing BrdU incorporation in DN3, DN4 and DP thymocytes of the indicated genotype. Mice were
injected with BrdU and the incorporation of BrdU in thymocytes was analyzed 12h later. Numbers indicate the percentage of cells within the
indicated region. Each histogram is representative of at least three mice.
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Reduced survival of Vav1/Itk/ thymocytes
Having determined that Vav1/Itk/ thymocytes did not show
a more severe block at the DN3 stage or reduced proliferation
compared with Vav1/ cells, we tested whether the survival
rate of Vav1/Itk/ thymocytes is altered compared with
Vav1/ and Itk/ thymocytes. Therefore, total thymocytes of
the various genotypes were ex vivo analyzed with Annexin V and
7-Amino-actinomycin D (7-AAD) stainings to distinguish between
early-apoptotic (Annexin V1 7-AAD–) and late-apoptotic/dead
(Annexin V1 7-AAD1) cells. While the percentage of early-
apoptotic cells was similar in WT, Vav1/ and Itk/ thymo-
cytes, it was much higher in Vav1/Itk/ thymocytes due to an
increase in early-apoptotic cells in the DP subset (Fig. 4A and B).
In contrast, the difference between Itk/ and Vav1/Itk/
cells in late-apoptotic/dead cells (Annexin V1 7-AAD1) was only
Figure 4. Increased cell death of Vav1/Itk/ DP thymocytes. (A) Dot plot showing Annexin V and 7-AAD stainings of ex vivo isolated thymocytes
of the indicated genotypes. Numbers indicate the percentage of cells in the respective quadrant. Each dot plot is representative of four mice. (B) Ex
vivo percentages of Annexin V1/7-AAD– total (left panel) or DP (right panel) thymocytes of the indicated genotypes. The diagram shows the
summary of all stainings performed (n5 4 for each genotype). (C) Immunoblot analysis of Bcl-2, Bcl-XL and BID expression levels in puriﬁed DP
thymocytes of the indicated genotype. PLC-g1 levels were used as loading control. Data shown are representative of three different experiments.
(D) Diagram showing the summary of pulse-chase BrdU labeling experiments. WT, Vav1/, Itk/ and Vav1/Itk/ mice were injected with a
single dose of BrdU and the percentage of BrdU1 DP thymocytes was monitored on days 2, 3 and 4. For each time point, at least four WT and
Vav1/Itk/, three Vav1/ and two Itk/ mice were analyzed.
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moderate (Fig. 4A). These data show that Vav1/Itk/ DP
thymocytes have increased fractions of early-apoptotic cells.
However, the expression of anti- or pro-apoptotic factors such as
Bcl-2, Bcl-XL and BID was similar in WT, Vav1/, Itk/ and
Vav1/Itk/ DP cells (Fig. 4C).
To investigate whether the increase in Annexin V1 cells in the
DP subset correlated with a reduced life span in vivo,
pulse-chase BrdU labeling experiments were performed. Mice
were injected with a single dose of BrdU and the percentage of
BrdU1 cells was monitored on days 2, 3 and 4. The peak
incorporation of BrdU in DP cells was observed on day 2 with
approx. 30–40% of BrdU1 WT cells. On day 4, the number
dropped to about 25%, indicating a 1.5-fold reduction
compared with day 2 (Fig. 4D). Similar BrdU incorporation
levels on day 2 were also observed in Vav1/ and Itk/ DP
cells. The numbers of BrdU1 Vav1/ DP cells on day 4 dropped
to about 12%, indicating a threefold reduction compared
with day 2 and a moderate reduction in the half-life compared
with WT DP cells (Fig. 4D). Itk/ DP cells had approx. 18% of
BrdU1 Vav1/ DP cells on day 4 (a 2.1-fold reduction). Within
the Vav1/Itk/ DP thymocyte subsets, about 50% of the cells
were BrdU1 on day 2 (Fig. 4D). The higher percentage of BrdU1
cells compared with WT DP thymocytes is most likely a conse-
quence of the increased BrdU incorporation observed in DN3/
DN4 cells on day 1 (Fig. 3C). However, on day 4 the number of
BrdU1 Vav1/Itk/ DP cells dropped to 4–5%, leading to an
11-fold reduction in BrdU1 cells (Fig. 4D). This indicates that the
in vivo life span of Vav1/Itk/ DP cells was dramatically
reduced compared with WT as well as Vav1/ and Itk/ DP
thymocytes.
Impaired positive selection of Vav1/ Itk/
thymocytes
Despite the reduced percentage of DP thymocytes, CD4 and CD8
SP thymocytes were still present in Vav1/Itk/ mice, although
in reduced numbers (Fig. 2C and D). To characterize the SP and
also the DP subsets in more detail, the expression levels of CD3
and CD5 were determined. The majority of WT and Itk/ CD4
SP thymocytes had high levels of CD3 and CD5 and therefore
were of a mature phenotype; only approx. 50% of Vav1/ CD4
SP cells had high levels of CD3 and CD5 (Fig. 5A and B). This
indicates an aberrant population of CD4 SP cells in Vav1/mice.
In contrast, there were essentially no CD3hi or CD5hi cells in the
CD4 SP subset in Vav1/Itk/ mice (Fig. 5A and B). A lack of
CD3hi but not of CD5hi cells was also observed within the CD8 SP
population (Fig. 5A and B).
Figure 5. Vav1/Itk/mice lack mature SP thymocytes. Histograms showing CD3 (A) and CD5 (B) expression on CD4 SP and CD8 SP thymocytes of
the indicated genotype. Numbers indicate the percentage of cells within the indicated region. Each histogram is representative of at least six mice.
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To evaluate whether the loss of mature SP cells in Vav1/Itk/
mice is caused by impaired positive selection, the CD69 expression
pattern on DP and SP thymocytes was determined. CD69 is
up-regulated upon TCR triggering on DP thymocytes at the onset of
positive selection and is subsequently down-regulated through the
progression to the SP stage [38–40]. While there was a reduction in
CD691 DP cells in Vav1/ mice compared with WT controls [10],
there was no further reduction in CD691 DP cells in Vav1/Itk/
mice compared with Vav1/ mice (data not shown). This is in
contrast to SP cells, since the CD691 population in Vav1/Itk/
mice was almost completely absent, while TCRbhi CD4 and CD8 SP
cells that still expressed CD69 could be readily detected in WT, Itk/
and also in Vav1/ SP thymocytes (Fig. 6A and B). To further analyze
whether positive selection is impaired in Vav1/Itk/ mice,
the Ca21 mobilization in DP thymocytes upon triggering of the TCR
was determined. While the Ca21 response was reduced in Itk/
and Vav1/ DP thymocytes compared with WT cells
(WT4Itk/4Vav1/), it was almost completely abolished in
Vav1/Itk/ DP thymocytes (Fig. 6C). Together, these data indicate
a block in positive selection of DP thymocytes in the combined absence
of Vav1 and Itk.
Itk/ and Vav1/Itk/ CD8 SP thymocytes have a
memory phenotype
Finally, it has been shown that Itk and Rlk are essential for the
development of conventional CD81 T cells. As a consequence, Itk/
mice and Itk/Rlk/mice are almost devoid of conventional CD81
T cells, while the remaining CD81 T-cell subsets have a memory
marker expression phenotype and several characteristics of innate-
like T lymphocytes, such as the up-regulation of CD44 and CD122,
the ability to produce rapidly IFN-g upon stimulation and their
dependency on IL-15 for their survival [33–35, 41]. Therefore, the
CD44 and CD122 as well as heat-stable antigen (HSA) expression
phenotype of Vav1/ and Vav1/Itk/ CD8 SP thymocytes was
determined. The majority of WT and Vav1/ CD8 SP cells already
contained a large fraction of HSAlo cells and were CD44lo and
CD122lo (Fig. 7), while a large population of Itk/ CD8 SP cells as
previously shown [33–35, 41] were CD44hi, CD122hi and HSAlo
(Fig. 7). The few remaining CD8 SP cells in Vav1/Itk/
thymocytes showed even a larger fraction of CD44hiCD122hi cells
compared with Itk/ thymocytes; however, the HSAlo/HSAhi
distribution was similar to that of WT and Vav1/ CD8 SP cells.
Figure 6. Impaired positive selection of Vav1/Itk/ DP thymocytes. (A) Dot plots showing the percentage of TCRbhiCD691 CD4 and CD8 SP
thymocytes of the indicated genotype. Numbers indicate the percentage of cells in the respective quadrant. (B) Diagram showing the summary of
panel (A). Each data point represents one mouse (n5 4). (C) Time course showing Ca21 response (measured as ﬂuorescence 405/525nm ratio) of DP
thymocytes of the indicated genotype that were labeled with Indo-1. Thymocytes were incubated for 1min with biotinylated anti-CD3 (1mg/mL)
and fully activated by crosslinking with streptavidin (indicated by the arrow). One representative experiment out of four is shown.
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Thus, the CD44 and CD122 expression proﬁle of CD8 SP thymocytes
indicated that Vav1, unlike Itk, is not essential for the development
of conventional CD81 T cells.
Discussion
Existing crosstalks between Vav1 and Itk and the similar
phenotype of Vav1/ and Itk/ T cells suggest that they act
in the same signaling pathways and perform (at least partially)
similar functions in activated T cells. In this study we further
investigated potential interdependences and similarities between
Itk and Vav1. To investigate whether the defects in peripheral
Vav1/ and Itk/ T cells are mechanistically similar, we tested
whether the defect of Itk/ T cells is rescued upon deletion of
the E3 ubiquitin ligase Cbl-b, as described for Vav1/ T cells [15].
The analysis of Itk/Cbl-b/ mice revealed partially restored
T-cell function if Itk/ T cells are released from the negative
regulation mediated by Cbl-b. Thus, our data provide additional
evidence that Vav1 and Itk fulﬁll similar functions in peripheral
T cells. In addition, we wanted to address genetically whether there
is functional redundancy between Vav1 and Itk during T-cell
activation by generating Vav1/Itk double-deﬁcient mice. However,
Vav1/Itk/ mice showed severely reduced numbers of periph-
eral T cells due to increased cell death of DP thymocytes and
impaired positive selection, thus indicating an essential role for the
combined activity of Itk and Vav1 during T-cell development.
The defect in Vav1-deﬁcient T cells is rescued upon deletion of
the E3 ubiquitin ligase Cbl-b, which mechanistically bypasses the
requirement for a CD28 costimulatory signal for the efﬁcient
formation of the immunological synapse [15]. Therefore, we
tested whether the phenotype of Itk/ T cells is rescued if Cbl-b is
deleted. An interaction between Vav1 and Itk has been demon-
strated [21] and Itk has been shown to regulate the actin cytos-
keleton [4, 31]. Thus, it was not surprising that we observed, in
agreement with another study [27], a rescue of the proliferation
and IL-2 production defect of Itk/ T cells in the absence of Cbl-
b. Furthermore, we also observed a partial rescue of IL-4
production in Th2 polarized Itk/Cbl-b/ CD41 T cells
compared with IL-4 of Itk/ CD41 T cells. It has also been shown
that the Ca21 response is still impaired in Itk/Cbl-b/ T cells,
as observed for Vav1/Itk/ cells [27]. This indicates that loss of
Cbl-b effects pathways independent or downstream of Ca21
mobilization. It is likely that the rescue of Itk-deﬁcient T cells upon
loss of Cbl-b is due to effects on the actin cytoskeleton, since it has
been demonstrated that loss of Cbl-b rescues actin polymerization
in Itk/ T cells in response to anti-CD3-coated beads [27]. In line
with this observation, lipid raft recruitment (which is dependent
on actin) to the site of anti-TCR or anti-TCR/CD28 beads was
improved in Itk/Cbl-b/ T cells compared with Itk-deﬁcient
cells [27]. A similar observation has been made in Vav1/Cbl-
b/ T cells [15]. Thus, the rescue appears mechanistically similar
to Vav1/Cbl-b/ T cells. Together, these data strengthen the
evidence that Itk and Vav1 have (partial) similar functions in
peripheral T cells and reveal additional mechanistic similarities
between Vav1/ and Itk/ T cells.
The CD4 and CD8 expression proﬁle of developing thymocytes
in Vav1/Itk/ mice is reminiscent of the one described for
mice deﬁcient for all three members (Vav1, Vav2 and Vav3) of
the Vav family. Vav1,2,3-null mice show a severe block at the
DN3 stage during T-cell development and it was reported that
there is a 50–100-fold reduction in thymocyte numbers [37].
However, it has not been reported whether Vav1,2,3-null DP
thymocytes show impaired survival compared with WT cells.
Among the Vav family, Vav1 has been shown to be the most
important member with respect to T-cell development, since
Vav1-deﬁcient mice showed already impaired thymocyte devel-
opment due to a block at the DN3 to DN4 stage [10, 11].
Figure 7. Itk-deﬁcient but not Vav1-deﬁcient CD8 SP thymocytes have a memory phenotype. CD44 (upper panel), CD122 (middle panel) and HSA
(lower panel) expressions on WT, Vav1/, Itk/ and Vav1/Itk/ CD8 SP thymocytes. Numbers in the histogram indicate the percentage of cells
within the region. Data are representative of two mice, except for Vav1/Itk/ thymocytes (n5 4).
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In contrast to Vav1/ mice, Itk/ mice do not show any
developmental defect within the DN subsets [36]. A recent study
comparing WT and Itk/ thymocytes in mixed BM chimeras
revealed a slightly impaired ability of Itk/ thymocytes to
reconstitute the DP subset due to subtle defects in pre-TCR
signaling [42], although we did not observe differences in the
incorporation of BrdU between WT and Itk/ DN3, DN4 or DP
thymocytes. The discrepancy between these results is most likely
caused due to the different experimental settings in which either
a competitive or a non-competitive development of Itk/
thymocytes in mixed BM chimeras or knockout mice, respec-
tively, was analyzed. The DN cell numbers, the DN1–4 proﬁle and
the proliferation rate of DN3, DN4 and DP thymocytes (as
measured by BrdU incorporation) were similar in Vav1/ and
Vav1/Itk/ mice. Thus, the dramatic loss of DP cells in
Vav1/Itk/ mice cannot be simply explained by a stronger
phenotype due to a more severe block at the DN3 stage in
Vav1/Itk/ thymocytes compared with Vav1/ thymocytes.
We rather favor the explanation that the combined deletion of Itk
and Vav1 alters intracellular signaling pathways that are required
for the survival of DP thymocytes, since Vav1/Itk/ DP cells
had a reduced life span in vivo compared with WT as well as
Vav1/ and Itk/ DP cells. Whether the survival signals are
transmitted by pre-TCR signals or via cytokine receptor signaling
or both remains to be determined. Although we clearly observed
an increase in early-apoptotic cells in Vav1/Itk/ compared
with Vav1/ DP thymocytes, the expression of pro- or
anti-apoptotic signaling molecules such as BclXL, Bcl-2 and BID
was indistinguishable between all genotypes analyzed. The
severely reduced numbers of peripheral T cells are most likely a
consequence of the diminished numbers of DP cells. However, the
remaining Vav1/Itk/ DP thymocytes showed also a defect in
positive selection, suggested by a further reduction in the Ca21
response in DP cells and the absence of CD691 SP thymocytes
compared with Vav1/ cells. Preliminary results also indicated
that Erk1/2 phosphorylation in Vav1/Itk/ was as severely
reduced as observed in Vav1/ DP cells (data not shown). Thus,
the combined activity of Vav1 and Itk is essential for the survival
of DP thymocytes and for positive selection.
A connecting molecule between Vav1 and Itk may be the
adaptor protein SLP76, which has been shown to interact with
both Vav1 and Itk [43]. The Vav1 interaction depends on SLP76
N-terminal tyrosine residues Y112 and Y128, while for the inter-
action with Itk Y145 is required [44]. SPL76 is essential for the
transition from DN to DP thymocytes, since SLP76/ mice have a
severe block at the DN3 stage [45, 46]. While the thymocyte
phenotype of SLP76/ mice is completely rescued by transgenic
expression of WT SLP76, transgenic expression of a triple Y112-
128-145F (Y3F) mutant SLP76 only partially rescued the SLP76-
deﬁcient phenotype. Y3F mice on an SLP76 ‘‘knockout’’ back-
ground (Y3F/DSLP76) developed DP but only few mature SP
thymocytes showed impaired up-regulation of CD69 and the
thymic cellularity was reduced by 90% [47, 48]. Thus, the Y3F/
DSLP76 phenotype partially resembles the thymocyte defect
observed in Vav1/Itk/ mice. However, the Vav1/Itk/
phenotype is more severe, since the percentage of DP cells was
much lower and peripheral T cells were severely diminished
compared with Y3F/DSLP76 mice. Further evidence that SLP76
may serve as a link between Vav1 and Itk was obtained from
‘‘knock-in’’ mutations of the respective tyrosine residues (Y to F),
since the activation of Vav1 or Itk was differentially affected by the
mutations. The phenotype of Y112-128F T cells was very similar to
the Vav1/ phenotype, while Y145F mice resembled the Itk-
deﬁcient phenotype, including the appearance of increased
percentages of innate-like CD81 T cells [49]. Although the lack of
Y122/128 or Y145 impaired the activation of Vav1 or Itk, respec-
tively, Vav1 or Itk were still able to interact with SLP76 [49].
Therefore, both molecules were still part of the TCR signalosome
and could partially function even in the absence of activation. This
may also provide a potential explanation as to why the thymocyte
phenotype of Y3F/DSLP76 mice appears to be weaker compared
with Vav1/Itk/ mice.
Vav proteins are the GDP/GTP exchange factor that activates
members of the Rho GTPases family, while Itk is a protein tyro-
sine kinase. However, the similarities in the T-cell development
phenotype of Vav1,2,3-null mice and Vav1/Itk double-deﬁcient
mice may suggest similar functions despite different enzymatic
activities, as indicated already for peripheral T cells (see [27] for
discussion). It has even been shown that Itk is required in a
kinase-independent way for the recruitment of Vav1 to the LAT/
SLP76 complex [21]. To test whether Itk has a kinase-indepen-
dent activity (i.e. a potential scaffolding function) also during
T-cell development, we initiated BM reconstitution experiments
expressing Itk or a kinase-dead version of Itk (Itk-KD).
Unfortunately, transduced Vav1/Itk/ BM cells reconstituted
the hematopoietic system of lethally irradiated WT mice
with very low efﬁciency (J. R. and W. E., unpublished observa-
tion). From more than 40 reconstituted mice we were able
to generate only one Itk-KD and one Itk-BM chimeric mouse.
Both Itk-KD and Itk could rescue the appearance of DP cells,
while the kinase activity of Itk was required to rescue the
appearance of mature SP thymocytes (see Supporting Informa-
tion). This preliminary result suggests different functional activ-
ities of Itk during T-cell development (in the absence of Vav1),
i.e. a scaffolding function of Itk for the generation of DP cells,
while the kinase activity of Itk is essential for positive selection of
DP thymocytes.
Despite the crosstalks between Vav1 and Itk, and the pheno-
typic similarities of Vav1- and Itk-deﬁcient peripheral T cells,
there is a different requirement for Vav1 and Itk during T-cell
development. As mentioned above, Vav1/ DN thymocytes show
a partial block at the DN3 stage, while Itk/ DN cells appear to
be relatively normal. As a consequence, Vav1/ mice have
reduced percentages of DP cells compared with Itk/ mice.
Furthermore, it has been recently shown that Itk is essential for
conventional T-cell differentiation [50]. Therefore, the majority
of CD81 T cells as well as an increased percentage of CD41 T cells
in Itk/ mice have a CD44hiCD122hi memory phenotype and
characteristics of innate-like T cells [33–35, 41, 51]. These
innate-like T cells develop in the thymus and therefore CD8 SP
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display already a CD44hiCD122hi phenotype [33, 34]. Although
we also observed an increase in CD44hi cells in Vav1/
peripheral CD81 T cells (data not shown), CD8 SP thymocytes
in Vav1-deﬁcient mice were similar to WT CD8 SP cells. Together,
these data clearly indicate that several processes during
T-cell development are uniquely regulated by either Vav1
or Itk.
In summary, our study reveals additional mechanistic simi-
larities between the T-cell activation phenotype of Vav1/ and
Itk/ T cells and indicates an essential role for the combined
activity of Vav1 and Itk for the survival of DP thymocytes and
positive selection during T-cell development.
Materials and methods
Mice
Animals used in this study were 6–12wk of age and bred and
maintained in the animal facility of the Medical University of
Vienna. Vav1/ [11], Itk/ [16] and Cbl-b/ [12] mice were
previously described and backcrossed to C57BL/6 (>N10).
Animal experiments were approved by the Federal Ministry for
Science and Research.
Flow cytometric analysis
All ﬂow cytometric analyses were performed on a FACSCalibur
(BD Biosciences). The following antibodies were from BD
Pharmingen: FITC-anti-CD3 (145-2C11), FITC-anti-CD44 (IM7),
PE-anti-CD5 (53-7.3), PE-anti-TCR-gd (GL3), PE-anti-CD122,
FITC-anti-HSA (M1/69); the following antibodies were from
Caltag: TC-anti-CD4 (CT-CD4), A647-anti-CD3, FITC-anti-CD45R
(RA3-6B2), FITC-anti-CD69 (H1.2FF3), PE-anti-CD25 (PC61
5.3); APC-anti-CD8a (53-6.7) and PE-anti-CD44 (IM7) were
used from eBioscience.
BrdU incorporation and pulse-chase experiments
Mice were injected intraperitoneally with 1mg (in 200 mL) BrdU.
After various time points, thymocytes were isolated, stained for
surface markers, and analyzed using the BrdU ﬂow kit (BD
Pharmingen).
Annexin V and 7-AAD analysis
Thymocytes were stained for CD4 and CD8 and later incubated in
Annexin-binding buffer (1106 cells/100 mL) containing 5mL of
FITC-Annexin V (Caltag) and 5 mL of 7-AAD (BD) for 20min at
room temperature. The percentage of apoptotic or dead cells was
determined by ﬂow cytometry.
Immunoblotting
DP thymocytes (5106) were lyzed in 100 mL of Carin lysis
buffer (20mM Tris-HCl, pH 8.0, 138mM NaCl, 10mM EDTA,
100mM NaF, 1% NP40, 10% Glycerol and 2mM NA-Vanadate)
supplemented with complete protease inhibitors (Roche).
Proteins were then separated on 8% SDS-polyacrylamide gels
and blotted onto PVDF membranes (Biorad). Anti- Bcl-2 (C-2),
anti-Bcl-XL (H-62) and anti-BID (D-19) were purchased from
Santa Cruz. Anti-PLCg1 was from Cell Signalling. Secondary
antibodies were from Jackson Immunoresearch.
Puriﬁcation of DP thymocytes
Thymocytes were stained with CD8a APC (53-6.7, eBioscience)
and puriﬁed via positive selection using anti-APC Beads (MACS
System, Miltenyi Biotec) according to the manufacture’s instruc-
tions. The purity of cells was assessed by ﬂow cytometry and was
routinely 490%.
Puriﬁcation of CD41 T cells
Pooled cell suspensions of lymph nodes and spleens were
incubated with biotinylated anti-CD8a, anti-CD11b, anti-CD11c,
anti-CD45R, anti-Ly-6G, anti-Ter119 and anti-NK antibodies in
PBS supplemented with 2% FBS. The CD41 T cells were then
puriﬁed by negative depletion using streptavidin beads (BD
Pharmingen) according to the manufacture’s instructions. The
purity of the cells was assessed by ﬂow cytometry and was
routinely 496%.
Calcium mobilization
Thymocytes were stained for CD4 and CD8 and labeled (1 106/
mL) for 30min with Indo-1 (1mM, Molecular Probes) and the
Ca21-dependent ﬂuorescence of Indo-1 was assessed by ﬂow
cytometry. Cells were stimulated with soluble bio-anti-CD3e
(1mg/mL) followed by crosslinking with 5mg/mL of streptavidin
(Sigma). Overall Ca21 content was assessed by the addition of
ionomycin (Sigma) at the end of each measurement. Data were
analyzed using CELLQuest (Becton Dickinson) and FlowJo
(TreeStar) software.
T-cell proliferation assay
Puriﬁed CD41 T cells were labeled with CFSE (Molecular Probes)
and cultured at 5 104 cells/well in 96-well ﬂat-bottom plates
(NUNC) coated with anti-CD3e (0, 0.3 or 1mg/mL) in a total of
100mL. Additional wells were coated with anti-CD3e (1 mg/mL)
plus anti-CD28 (3 mg/mL); 48 h later, the cells were harvested
and analyzed by ﬂow cytometry.
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Differentiation of T helpers
Puriﬁed CD41 T cells were stimulated with plate-bound
anti-CD3e (1mg/mL) and plate-bound anti-CD28 (3 mg/mL)
on 48-well plates. For Th2 polarizing conditions, cells were
activated in the presence of recombinant IL-4 (250U/mL),
anti-IFN-g (10 mg/mL) and anti-IL12 (10 mg/mL). CD41 T-cell
cultures were split 1:2 on day 3 after activation. After 6 days in
culture, cells were puriﬁed over a lymphoprep gradient and
restimulated (5105 cells/mL) with plate-bound anti-CD3e
(0.1 mg/mL). Supernatant for cytokine quantiﬁcation was
collected 12 h later.
Cytokine measurement
IL-2 and IL-4 cytokine levels were determined by ELISA (BD).
Statistical analysis
All data are expressed as the mean7SEM. Statistical analysis was
performed by using Student’s t-test (po0.05, po0.01,
po0.001; n.s., not signiﬁcant).
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Transcriptional pathways controlling the development of CD44hi
memory phenotype (MP) T cells with ‘‘innate-like’’ functions are
not well understood. Here we show that the BTB (bric-a-brac,
tramtrack, broad complex) domain-containing protein promyelo-
cytic leukemia zinc ﬁnger (PLZF) is expressed in CD44hi, but not in
CD44lo, CD4 T cells. Transgenic expression of PLZF during T cell
development and in CD4 and CD8 T cells induced a T cell intrinsic
program leading to an increase in peripheral CD44hi MP CD4 and
CD8 T cells and a corresponding decrease of naïve CD44lo T cells.
The MP CD4 and CD8 T cells produced IFN upon PMA/ionomycin
stimulation, thus showing innate-like function. Changes in the
naïve versus memory-like subset distribution were already evident
in single-positive thymocytes, indicating PLZF-induced T cell devel-
opmental alterations. In addition, CD1d-restricted natural killer T
cells in PLZF transgenic mice showed impaired development and
were severely reduced in the periphery. Finally, after anti-CD3/
CD28 stimulation, CD4 transgenic T cells showed reduced IL-2 and
IFN production but increased IL-4 secretion as a result of enhanced
IL-4 production of the CD44hiCD62L subset. Our data indicate that
PLZF is a novel regulator of the development of CD44hi MP T cells
with a characteristic partial innate-like phenotype.
innate-like lymphocytes  T cell development  transgenics
Peripheral CD4 and CD8 T cell subsets have been tradi-tionally divided into naïve CD44loCD62L and memory
CD44hiCD62L populations, while the surface expression phe-
notype of the latter population also resembles recently activated
T cells (1, 2). In recent years it became clear that the memory T
cell subset is not a population consisting only of true antigen-
specific memory cells that developed in response to a foreign
antigen. Rather, the memory population contains a variety of
different T lymphocyte subsets: some may have acquired their
memory marker phenotype through homeostatic proliferation,
whereas others show immediate effector function and may play
a role in the front-line defense against certain bacterial infec-
tions. These additional cells were described as memory pheno-
type (MP) T lymphocytes, and some subsets of the MP popu-
lation are also described as innate T cells (3, 4). Certain MP or
innate-like T cells are derived from double-positive (DP) thy-
mocytes, and at least some of these cells can be selected on
non-classical MHC class Ib molecules (5), achieved by interac-
tion with hematopoietic cells rather than with thymic epithelial
cells (6). Among the innate-like T lymphocyte subsets that have
been characterized are natural killer T cells (NKT cells) (7–9),
H2-M3 specific T cells (10), mucosal-associated invariant T cells
(11), and also CD8 expressing intraepithelial lymphocytes of
the gut (12).
Important insight about signaling molecules that are involved
in conventional versus innate-like T cell differentiation is pro-
vided from studies on Tec family kinase-deficient mice (4).
IL2-inducible T-cell kinase (Itk) and resting lymphocyte kinase
(Rlk) are essential for the development of conventional CD8 T
cells. As a consequence, Itk/ mice and Itk/Rlk/ mice
are almost devoid of conventional CD8 T cells, whereas the
remaining CD8 T cell subsets have several characteristics of
innate-like T lymphocytes (13–16). Conventional CD4 T cells
are also reduced in the absence of Itk; thus, Itk/ mice have
also a relative increase in innate-like MP CD4 T cells (17). In
addition, Itk/ mice have reduced numbers of NKT cells
(18–20). Another important signaling cascade that has been
shown to differentially influence conventional and innate-like
MP T lymphocyte development involves the signaling lympho-
cyte activation molecule and signaling lymphocyte activation
molecule-associated protein (21–24).
To gain more insight into the function of Itk in T cells,
Affymetrix microarray experiments were performed to iden-
tify genes that are differentially expressed between WT and
Itk/ T cells (K.E.M.B., unpublished work). One of the
genes identified that was up-regulated in Itk/ CD3 T cells
was Zbtb16, which encodes for the transcriptional repressor
promyelocytic leukemia zinc finger (PLZF). PLZF regulates
several biological processes and has also been implicated in
tumorigenesis (25). PLZF belongs to the family of BTB
(bric-a-brac, tramtrack, broad complex) domain-containing
zinc finger factors (BTB-ZF) (25, 26), and important functions
in the T cell lineage have been described for several members
of the BTB-ZF gene family (27).
In this study we investigated the role of PLZF in T cells. We
show that PLZF was expressed in the CD4CD44hi T cell lineage
but not in the naïve CD4CD44lo subset, whereas CD8 T cells
did not express detectable levels of PLZF. Enforced transgenic
expression of PLZF in T lymphocytes induced a T cell intrinsic
program leading to an increase in CD44hi MP T cells and a
corresponding decrease of naïve CD44lo T cells. The CD44hi
population produced IFN upon PMA/ionomycin stimulation,
thus sharing characteristics with innate T lymphocytes. Trans-
genic CD4 T cells showed enhanced IL-4 levels after anti-CD3/
CD28 stimulation and an increase in a CD44hiCD62L IL-4-
producing subset. Together, our data indicate that PLZF is a
novel transcriptional regulator for the development of CD44hi
MP T cells with innate-like features.
Results
Expression of PLZF Is Restricted to CD4CD44hi T Cell Subsets. We
have performed Affymetrix microarray analysis to identify genes
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that are differentially expressed between WT and Itk/ CD3
T lymphocytes during T cell activation (K.E.M.B., unpublished
work). One gene identified that was already expressed at higher
levels in unstimulated Itk-deficient CD3 T cells compared with
WT cells was Zbtb16, which encodes for the transcriptional
regulator PLZF. Immunoblot analysis confirmed the up-
regulation of PLZF in Itk/ T cells (Fig. 1A). Because T cell
subsets in Itk/mice have a T cell memory phenotype (13–17),
we investigated whether the increase in the expression of PLZF
was caused by a higher percentage of MP T cells in Itk/mice.
Therefore, WT CD4 and CD8 T cell subsets were sorted into
CD62L and CD62L fractions. Immunoblot analysis of these
sorted subsets revealed that PLZF was expressed in the WT
CD4CD62L T cell population but in neither CD4CD62L
nor CD8 T cells (Fig. 1A). The majority of WT cells within the
CD62L subset are naïve CD44lo T cells, and there is only a
minor fraction of CD44hiCD62L cells. To test whether the
CD44hiCD62L population expressed Zbtb16, RT-PCR analysis
using RNA from sorted CD44loCD62L, CD44hiCD62L, and
CD44hiCD62L CD4 T cell subsets was performed. In agree-
ment with the protein expression data, the RT-PCR analysis
revealed expression of Zbtb16 in CD44hiCD62L cells (Fig. 1B).
In addition, low-level expression of Zbtb16 was observed in
CD44hiCD62L cells, in contrast to CD44loCD62L cells (Fig.
1B). Together, this set of data indicated a correlation between
PLZF expression and the CD44hi MP CD4 T cell subset. To
investigate a potential role of PLZF in the generation and/or
function of the CD4CD44hi T cell subset, gain-of-function
experiments were performed. Therefore, transgenic mice ex-
pressing PLZF under the control of Cd4 cis-regulatory element
were generated (Fig. 1C), which direct expression from the DN3
stage on, and remain active in, CD4 and CD8 T cell subsets
(data not shown). Further, the transgenic expression vector
contained an IRES-GFP cassette to detect transgenic T cells by
GFP expression. Three different founder lines (lines 1, 2, and 3)
were selected for further studies. In thymocytes, PLZF was
expressed at higher levels in line 2 compared with line 1,
correlating with GFP levels [supporting information (SI) Fig.
S1]. Furthermore, transgenic peripheral CD4 T cells showed
high levels of PLZF protein compared with WT MP
CD4CD62L T cells, although PLZF levels were only slightly
enhanced in line 2 compared with line 1 (Fig. S1).
Transgenic Expression of PLZF Induces Dose-Dependent Changes in
CD44 and CD62L Expression on Peripheral T Cells. PLZF transgenic
mice displayed a moderate alteration in peripheral T cell num-
bers and had increased CD4/CD8 ratios (Fig. S2 A and B).
Because the PLZF expression pattern suggested a specific
function of PLZF in the CD44hi T cell subset, the CD44 versus
CD62L expression pattern on peripheral splenic and LN T cells
was determined in PLZF transgenic mice. This analysis revealed
a decrease in the CD44loCD62L naïve CD4 and CD8 T cell
subset and a corresponding increase of the CD44hiCD62L
population in the presence of PLZF (Fig. 2A and Fig. S3). We
also noted an increase in the CD44loCD62L population in
PLZF transgenic mice compared with WT mice. Furthermore,
the percentage of CD44hiCD62L as well as CD44hiCD62L
cells increased with increasing levels of PLZF expression, indi-
cating a dose-dependent effect of PLZF (Fig. 2A and Fig. S2C).
Transgenic CD4 and CD8 T cells showed no up-regulation of
CD25 and CD69 activation marker expression (Fig. 2B), indi-
cating that the presence of CD44hi T cell population is not the
result of T cell activation.
PLZF Induces a T Cell Intrinsic Program that Leads to a Change in the
CD44 and CD62L T Cell Subset Distribution. Another transgenic
founder line (line 3) had an X-chromosomal transgene insertion.
Fig. 1. PLZF expression in peripheral T cells is restricted to CD4CD44hi T cells
(A) Protein expression levels of PLZF inWT and Itk/ peripheral CD3 T cells
(Left), and in WT peripheral CD4 and CD8 T cell subsets that were sorted into
CD62L and CD62L populations (Right). The equivalent of 1.5 106 cells was
loaded per lane. Actinwas used as loading control. Data are representative of
two different experiments. (B) Semiquantitative RT-PCR analysis shows
Zbtb16 expression in variousWT peripheral CD4 T cell subsets. Hprt1 expres-
sion was used as loading control. The triangle indicates ﬁvefold dilutions of
input.Dataare representativeof two independentexperiments. (C) Schematic
map of the transgenic construct used for generation of Zbtb16 transgenic
mice. The thickbar indicates splicingmodule fromtheCd4 locus. (LCR/TE, locus
control region and thymocyte enhancer from the Cd4 locus; E4, proximal Cd4
enhancer; P4, Cd4 promoter.)
Fig. 2. Forced expression of PLZF induces a T cell intrinsic CD44hi phenotype
in CD4 and CD8 T cells. (A) CD62L and CD44 expression pattern on CD4
(Upper) and CD8 (Lower) splenic T cells from WT and PLZF transgenic mice
(lines 1 and 2). Numbers in the dot plots indicate the percentage of cells in the
respective quadrant. Data are representative of at least three independent
experiments for each transgenic line. (B) CD69 and CD25 expression on CD4
andCD8 splenic T cells isolated fromWTandPLZF transgenicmice. CD3-gated
dot plots indicate gating regions for the histogram analysis. Data are repre-
sentative of at least three independent experiments. (C) CD62L and CD44
expression pattern on GFP (Left) or GFP (Right) CD4 T cells isolated from
the spleen of female PLZF mice (line 3). Numbers indicate the percentage of
cells in the respective dot plot quadrants. Gating areas for GFP and GFP
populations are shown in the CD3 T cells histogram on the left. Data are
representative of ﬁve independent experiments.
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Transgenic males of this line transmitted the mutation exclu-
sively to their female offspring. Furthermore, almost all T cells
of male mice of line 3 carrying the PLZF transgene were GFP
(data not shown), whereas in hemizygous female mice of line 3,
approximately only half of the T cells were GFP (Fig. 2C).
Because there were similar numbers of GFP and GFP T cells
in female transgenic mice, we concluded that PLZF-expressing
T cells have no major developmental advantage or disadvantage
over non-transgenic T cells. Similar to transgenic lines 1 and 2,
GFP CD4 and CD8 T cells in male and female mice of line
3 displayed the altered CD44/CD62L expression pattern in the
spleen (Fig. 2C and data not shown), whereas the GFP
population in female transgenic mice showed a CD44/CD62L
distribution similar to WT mice (Fig. 2C). Thus, PLZF induces
a T cell-intrinsic genetic program in both CD4 and CD8 T
cells that leads to a dramatic alteration in the CD44/CD62L
subset distribution.
CD44hi T cells in PLZF Transgenic Mice Develop in the Thymus and Have
a Memory Phenotype with Innate-Like Characteristics. To determine
whether the CD44hi T cells emerge already in the thymus, a
comprehensive analysis of thymocyte development was per-
formed. In contrast to WT cells, transgenic PLZF thymocytes
had increased percentages of SP cells and reduced numbers of
DP cells (Fig. 3A and Fig. S4A). However, the expression of CD3
and HSA on the various subsets was similar between WT and
PLZF thymocytes (Fig. 3A). Furthermore, CD4SP and CD8SP
PLZF transgenic thymocytes showed a larger fraction of cells
that had down-regulated CD62L expression compared with WT
SP cells, and PLZF transgenic CD8SP cells displayed an increase
in CD44hi subsets (Fig. 3B). CD122 expression was similar in WT
and PLZF transgenic SP cells (Fig. 3B). In agreement with the
thymic emergence of PLZF MP T cells, T cells with an altered
CD44/CD62L profile were already present in 14-day-old PLZF
transgenic mice (Fig. S5).
The CD44hi MP T cell population of WT mice is composed of
several T cell subsets (3, 4). To test whether CD44hi SP cells and
peripheral T cells in PLZF transgenic mice have immediate
effector function, thymocytes and splenocytes were isolated and
stimulated ex vivo with PMA/ionomycin. In addition, we com-
pared the innate properties of PLZF transgenic T cells with
Itk/ SP thymocytes and splenocytes, as Itk/ mice have a
large number of innate-like T cells (13–16). Similar to the WT
CD4SP and CD8SP CD44hi populations, CD4SP and CD8SP
CD44hi PLZF transgenic T cells produced IFN, although the
percentage of IFN-producing CD4SP cells was reduced within
the CD44hi fraction (Fig. 3C and Fig. S4B). Itk/ SP thymo-
cytes, as reported previously (13, 14), showed increased produc-
tion of IFN compared with WT cells. In the periphery, the
percentage of IFN-producing CD4 T cells within the CD44hi
population was reduced in PLZF transgenic mice compared with
WT controls (Fig. 3D and Fig. S4C). In contrast, there was an
increase in IFN-producing CD44hi CD8 T cells. The relative
percentage of PLZF transgenic IFN-producing CD8 T cells
within the CD44hi population was moderately increased com-
pared with WT MP T cells, but not as high as in innate-like
Itk/ CD8 T cells (Fig. 3D and Fig. S4C). Thus, despite the
dramatic increase in the numbers of MP T cells in PLZF
transgenic mice, the PLZF MP population had similar innate-
like functions as WT MP subsets.
Many innate T lymphocytes such as NKT cells (7) and
innate-like CD8 T cells in Itk/ mice require IL-15 for their
survival (13, 15). IL-15 signals via the IL-15 receptor complex,
which is composed of several subunits including CD122 (28).
PLZF transgenic and WT CD44hiCD62L CD8 T cells dis-
played similar up-regulated CD122 expression levels, and the
percentage of CD122 cells within this transgenic subset was
even slightly increased compared with the WT subset (Fig. S6).
Together, these data indicate that enforced expression of PLZF
leads to the development of CD44hi MP T cells with innate-like
characteristics.
Impaired NKT Cell Development in PLZF Transgenic Mice. Because
NKT cells have a CD44hiCD62L surface expression phenotype
(7), we investigated whether PLZF expression led to an increase
in NKT cells. To have internal staining controls, the analysis was
performed in female PLZF transgenic mice of line 3, which have
both GFP and GFP cells within the T cell subset. CD1d
Fig. 3. MP T cells in PLZF transgenic mice develop in the thymus and have innate-like characteristics. (A) CD4 and CD8 expression on WT and PLZF transgenic
(line 1) thymocytes. Histograms (Right) showHSA and CD3 expression levels on CD4SP and CD8SP cells. (B) CD44, CD62L, and CD122 expression pattern on CD4SP
(Upper) and CD8SP (Lower) thymocytes. Numbers below histograms indicate the percentage of cells in the indicated region. Data in A and B are representative
of at least three mice. (C and D) Intracellular IFN expression in ex vivo PMA/ionomycin-stimulated WT, PLZF transgenic (line 1), and Itk/ CD4SP and CD8SP
thymocytes (C) and CD4 and CD8 splenic T cells (D). Numbers in the dot plots indicate the percentage of cells in the respective quadrants. Data in C and D are
representative of three experiments.










tetramers (CD1d-tet) loaded with the GalCer analogue PBS57
were used to detect invariant NKT cells. This analysis revealed
that CD1d-tet NKT cells were severely reduced in the GFP T
cell subset, whereas NKT cells were readily detected within the
GFP subset (Fig. 4A and Fig. S7A). Next, we investigated
whether the peripheral reduction of NKT cells is caused by a
(partial) block during thymic NKT cell development. Early
CD1d-tet NKT cells are HSAhi, followed by a HSAlo stage (7,
8). Preliminary results indicated that the GFP/GFP ratio was
approximately 50:50 in the HSAhiCD1d-tet fraction, whereas
the percentage of GFP cells declined in the HSAloCD1d-tet
fraction (data not shown). This indicated a defect in the tran-
sition to or within the HSAlo fraction. The thymic CD1d-tet
HSAlo subset can be further divided into three stages that follow
a CD44NK1.1 (stage 1), CD44hiNK1.1 (stage 2), and
CD44hiNK1.1 (stage 3) pattern (7, 8). Our analysis revealed
that the transition from stage 2 to stage 3 is impaired in PLZF
transgenic mice, indicated by an increase in stage 2 and a
corresponding decrease in stage 3 NKT cells (Fig. 4B and Fig.
S7B). This suggests that enforced expression of PLZF impairs
NKT cell development.
Transgenic Expression of PLZF Alters the Cytokine Profile of Naïve
(CD44lo) and MP (CD44hi) CD4 T Cells. Next we analyzed whether
PLZF expression changed the cytokine production of CD4 T
cells upon T cell receptor-mediated activation. Total CD4 T
cells were isolated from WT or PLZF transgenic mice and
stimulated with anti-CD3/CD28. IL-2 levels were severely im-
paired in PLZF transgenic CD4 T cells (Fig. 5A), and PLZF
transgenic CD4 T cells produced reduced amounts of IFN
compared with WT CD4 T cells. In contrast, they showed
dramatically increased levels of IL-4 compared with WT controls
(Fig. 5A).
To investigate which subset is responsible for the dramatic
increase in IL-4, CD44loCD62L, CD44hiCD62L, and
CD44hiCD62L, WT and PLZF transgenic CD4 T cells were
sorted and activated with anti-CD3/CD28. All subsets of WT and
PLZF transgenic CD4 T cells produced IL-2, whereas IFN
was secreted by CD44hiCD62L and CD44hiCD62L T cells
(Fig. 5B). However, transgenic T cells showed reduced IL-2 and
IFN production compared with WT cells. WT CD44hiCD62L
cells produced high levels of IL-4, whereas IL-4 levels in this
subset of transgenic T cells were reduced (Fig. 5B). This is in
contrast to the CD44hiCD62L subset, which showed enhanced
IL-4 levels in PLZF transgenic mice. Thus, the presence of this
IL-4 producing CD44hiCD62L subset explains why total CD4
T cells produce elevated levels of IL-4. Although Tbx21 (encod-
ing for T-bet) and Gata3 are known to be major transcription
factors responsible for IFN and IL-4 expression of Th1 and Th2
cells, respectively, no major difference in the expression of Tbx21
and Gata3 in the various subsets was observed (Fig. S8).
Discussion
In this study we showed that the BTB-ZF factor PLZF is
predominantly expressed in CD44hi CD4 T cells. Enforced
expression of PLZF during T cell development and in peripheral
T cells led to the appearance of a large population of peripheral
T cells with a CD44hi memory phenotype that were able to
produce IFN upon ex vivo PMA/ionomycin stimulation. PLZF
expressing (i.e., GFP) T cells in female mice of line 3 showed
an MP despite the presence of similar numbers of GFP T cells
with a naïve phenotype, thus indicating a T cell intrinsic defect.
Together with the observations that the cells were not activated
and that PLZF T cells showed no increased BrdU incorporation
(data not shown), this also suggests that the CD44hi T cells are
not generated via homeostatic proliferation (29). In addition,
Fig. 4. Impaired NKT cell development in PLZF transgenic mice. (A) NK1.1
expression and CD1d-tet binding on GFP (Left) and GFP (Right) CD3
transgenic splenocytes (line 3). Numbers in the dot plots indicate the percent-
age of cells in the respective quadrant. Histogram shows gating region for
GFP and GFP T cell populations. Data shown are representative of three
mice. Similar results have also been obtained for line 1 (n  3 mice). (B)
Histogram (Upper) shows gating region for GFP and GFP thymocytes (line
3). Dot plots indicate gating regions for CD1d-tet HSAlo NKT cells. CD44 and
NK1.1 expression on CD1d-tet HSAlo NKT cells (Lower). Numbers in the dot
plots indicate the percentage of cells in the respective quadrant. Data shown
are representative of three mice. Similar results have also been obtained for
line 1 (n  3).
Fig. 5. PLZF alters the cytokine proﬁle of T cell receptor-stimulated CD4CD44lo and CD4CD44hi T cells. (A) Diagrams show IL-2, IFN, and IL4 production in
puriﬁedWT and PLZF transgenic (lines 1 and 2) CD4 T cells stimulated for 48 hwith plate-bound anti-CD3/CD28. For IFN detection, only cells with95%purity
were used to exclude ‘‘contaminating’’ IFN-producing CD8 T cells. The cytokine levels in the supernatantswere determined by ELISA in duplicates. Data shown
are representative of three independent experiments. (B) IL-2, IFN, and IL-4 production of WT or PLZF transgenic (line 1) CD4 T cells that were sorted into
CD44loCD62L, CD44hiCD62L, and CD44hiCD62L subsets. Cells were stimulated and cytokines determined as in A. Data shown are representative of four
independent experiments (three with line 1 and one with line 3; male mice).
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changes in the naïve versus memory-like subset distribution were
already evident at the SP stage during T cell development. This
indicates that the MP T cell populations in PLZF transgenic mice
are at least in part derived from DP thymocytes, like other MP
T cells (3, 4). We therefore propose that PLZF induces a
transcriptional program that leads to the generation of CD44hi
MP T cells that share certain features with innate-like T cells.
The observations that PLZF is up-regulated in the Itk/ T
cell population (which is enriched in innate-like T cells) and that
PLZF expression is restricted to the CD4CD44hi population
revealed a correlation between PLZF expression and MP CD4
T cells. A more direct link between PLZF and innate-like MP T
cells is established by the CD44hi phenotype of transgenic T cells.
Thus, ectopic PLZF expression leads to an increase of those T
cell subsets that express PLZF in WT cells, indicating that PLZF
can convert CD4CD44lo subsets into CD4CD44hi populations.
Furthermore, endogenous PLZF was expressed in transgenic
CD44hi but not CD44lo CD4 T cells (data not shown), an
expression pattern identical to the one in WT CD4 T cell
subsets. This indicates that transgenic PLZF induced the differ-
entiation of a distinct lineage of MP T cells with innate-like
characteristics. Interestingly, immunoblot analysis did not reveal
expression of PLZF in innate-like CD8 T cells. However, PLZF
also induced the CD44hi phenotype in CD8 T cells, suggesting
that PLZF may induce similar transcriptional programs in CD4
and CD8 T cell lineages, and possibly indicating the existence of
an endogenous factor that specifically directs the development of
CD44hi MP CD8 T cells.
We demonstrated that CD4 and CD8 MP T cells in PLZF
mice possess innate-like characteristics. The increase in IFN-
producing transgenic CD44hi CD8 T cells is similar to the one
observed in innate-like Itk/ CD8 T cells, although the
percentage of IFN-positive cells within the CD44hi population
is higher in the absence of Itk. Further, only peripheral MP
CD8 T cells and not CD8SP MP thymocytes in PLZF trans-
genic mice showed an increase in IFN-producing CD44hi cells
upon PMA/ionomycin stimulation, suggesting a further matura-
tion of innate-like functions in the periphery. In contrast,
IFN-producing CD44hi cells were increased in the thymus and
in the periphery in Itk/ mice. These findings may indicate a
different subset composition and/or differential regulation of
innate-like CD8 T cells in PLZF and Itk/ mice. PLZF MP
CD4 T cells produced IFN as well; however, the percentage
of IFN-positive CD4 T cells within the CD44hi population was
reduced. Moreover, upon anti-CD3/CD28 activation we ob-
served reduced cytokine production in all subsets of PLZF
transgenic CD4 T cells compared with WT CD4 T cell
subsets, except for the dramatic increase of IL-4 production in
the CD44hiCD62L subset. It is possible that PLZF may down-
modulate the IL-2 and IFN response by binding to cytokine loci
and recruiting co-repressors including nuclear receptor co-
repressor and histone deacetylase (25), or by repressing the
expression of an important signaling molecule or transcription
factor required for cytokine expression. Alternatively, but not
mutually exclusively, PLZF expression may lead to a different
cellular composition of peripheral CD4 T cells, even though we
could not observe any altered expression of T-bet and Gata-3 in
the various subsets of PLZF transgenic mice compared with WT
mice. A ‘‘candidate’’ innate-like population are NKT cells that
share a CD44hi expression phenotype with PLZF transgenic T
cells (7–9). A recent study has shown that PLZF is primarily
expressed in CD1d-restricted NKT cells (30). However, other
MP T cell subsets may express PLZF as well, as PLZF expression
was up-regulated in Itk/ T cells, which have diminished
numbers of NKT cell subsets compared with WT T cells (19, 20).
Remarkably, NKT cell numbers in mice lacking PLZF were
severely reduced, and they also displayed impaired cytokine
expression patterns (30). Unexpected given this essential role of
PLZF for NKT cell development, we observed a severe reduc-
tion of NKT cells in PLZF expressing mice compared with WT
mice. One explanation, that both PLZF-deficient and PLZF
transgenic mice have diminished numbers of NKT cells, may
come from the observation that stage 1 and stage 2 NKT cells
express the highest level of PLZF and down-regulate PLZF
expression at stage 3 (30). Thus, enforced transgenic expression
of PLZF may partially block NKT cells at this stage.
Taken together, our study gives insight into transcriptional
control mechanisms that regulate conventional versus MP T cell
development and suggest that PLZF is an important regulator in
this process. Further studies aiming to identify and characterize
the genetic program that is induced by PLZF are required to
further elucidate these developmental processes.
Materials and Methods
Generation of the PLZF Transgenic Construct. The transgene expression cassette
consisted of the Cd4 Locus control region/thymocyte enhancer, the Cd4 prox-
imal enhancer/promoter, and a splicing module from silencer-less Cd4 intron
1 sequences, followed by IRES-GFP-polyA sequences, and was provided by
Ichiro Taniuchi (Riken, Yokohama, Japan). The cDNA sequence encoding for
PLZF (MGI: 103222; nucleotide 249-2352) was inserted as an EcoRI fragment
upstream of the IRES-GFP module.
Generation of PLZF Transgenic Mice. The linearized construct was microin-
jected into a pronucleus of fertilized C57BL/6N inbred oozytes that were
transferred afterward into the oviduct of pseudopregnant foster mothers
according to standard protocols for generating transgenic mice (31). Trans-
gene integrations were identiﬁed by PCR of tail DNA with GFP-speciﬁc prim-
ers. Of several identiﬁed transgenic founders, we selected lines C57BL/6N-
Tg(Cd4-Zbtb16,GFP)141–143 Biat (lines 1–3 for brevity) based on the GFP
expression levels.
Mice. Animals used in this study were bred and maintained in the animal
facility of the Medical University of Vienna. Analyzed mice were 6 to 8 weeks
of age unless indicated otherwise. All animal experiments were approved by
the Federal Ministry for Science and Research.
Flow Cytometric Analysis and Antibodies. The following antibodies were used
for the staining: PE-anti-CD62L, PE-anti-CD122, PE-Cy7-anti-CD4, PE-anti-IFN,
and APC-anti-IL-4 from BD Pharmingen; APC-anti-CD8 (53–6.7), APC-anti-
CD62L, PE-Cy7-anti-CD44, APC-anti-CD25, APC-anti-NK1.1, PE-anti-CD3e, and
Pb-anti-CD3e from eBioscience; and A647-anti-CD3 from Caltag. PBS57-
loaded and unloaded CD1d tetramers (conjugated with PE) were obtained
from the National Institutes of Health tetramer facility and used according to
the instructions. Flow cytometry was performed on LSRII (BD Biosciences) and
data analyzed using FlowJo software.
Purification of T Cells and Cell Sorting. CD3 T cells were isolated by incubating
cell suspensions of spleens (in PBS solution supplemented with 2% FCS) with
biotinylatedanti-CD11b, anti-CD11c, anti-CD45R, anti-Ly-6G, anti-Ter119, and
anti-NK antibodies, followed by negative depletion using streptavidin beads
(BD Pharmingen) according to the manufacturer’s instructions. For the isola-
tion of CD4 T cells, biotinylated anti-CD8 antibodies were added to the
depletion antibody mixture. The purity of either CD3 or CD4 T cells was
assessed by ﬂow cytometry and was routinely 90%–95%. For cell sorting,
CD4 T cells were incubated with anti-CD4, anti-CD44 and anti-CD62L, and
CD4 T cells subsets were sorted into CD44loCD62L, CD44hiCD62L, and
CD44hiCD62L populations with a FACSAria cell sorter (Becton Dickinson).
Activation of T Cells and Cytokine Measurement. Puriﬁed or FACS-sorted CD4
T cells (5  105) or T cell subsets (5  105) were stimulated with plate-bound
anti-CD3 (1 g/ml) and plate-bound anti-CD28 (3 g/ml) on 48-well plates.
CD4 T cells were grown in 1 ml RPMI1640 Glutamax-I (Invitrogen), supple-
mented with 10% FCS (Invitrogen), antibiotics, and 2-mercaptoethanol (In-
vitrogen). The supernatants for cytokine quantiﬁcation were collected 48 h
later. IL-2, IL-4, and IFN cytokine levels were determined by ELISA (BD
Pharmingen).
For PMA/ionomycin stimulation, thymocytes or splenocytes were incubated
for 5 h with PMA (50 ng/ml) and ionomycin (500 ng/ml) (Sigma) in the presence
ofGolgiSTOP (BDBiosciences). Surface staining for CD3, CD4, CD8, andCD44was
performed, and subsequently cells were ﬁxed and permeabilized with Cytoﬁx/
Cytoperm solution (BD Pharmingen) and further stained with PE-anti-IFN.










Statistical Analysis. All data are expressed as mean  SEM. Statistical analysis
was performed by using a Student t test. The P values were deﬁned as
following: *P  0.05; **, P  0.01; ***, P  0.001; n.s., not signiﬁcant.
Note Added in Proof. While this articlewas in revision, Savage et al. (32) reported
similar data as described in our study. They observed that transgenic expression
of PLZF induced CD4SP thymocytes and CD4 T cells to acquire a CD44hi pheno-
type. In addition, Savage et al. reported that PLZF is primarily expressed in
CD1d-restricted NKT cells and that PLZF-deﬁcient mice have impaired NKT cell
differentiation and effector function (in agreement with ref. 30).
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Immunoblotting. Purified cells (5  106/100 l) were lysed in
Carin lysis buffer (20 mM Tris-HCl pH 8.0, 138 mM NaCl, 10
mM EDTA, 100 mM NaF, 1% Nonidet P-40, 10% glycerol, 2
mM NA-vanadate) supplemented with complete protease inhib-
itors (Roche). Proteins were then separated on 8% SDS-
polyacrylamide gels and blotted onto PVDF membranes (Bio-
Rad). Anti-PLZF antibody (mAb 2A9) was purchased from
Calbiochem. Anti-actin was from Sigma and secondary antibod-
ies were from Jackson Immunoresearch.
cDNA Synthesis and RT-PCR. Total RNA was isolated from sorted
peripheral CD4 T cell subsets using TRI reagent (Sigma).
cDNA synthesis was performed using random hexamer primers
and SuperScript II reverse transcriptase (Invitrogen) according
to the manufacturer’s protocol. Cycling conditions for RT-PCR
were 4 min at 95°C, followed by 25 to 35 cycles of 30 sec at 95°C,
30 sec at 58°C, and 40 sec at 72°C. The primer sequences were:
Hprt1, F 5-ATT GTG GCC CTC TGT GTG CT; R 5-TTG
CGC TCA TCT TAG GCT TTG; Zbtb16, F 5-CCC AGT GGA
GAA GCA TTT GG; R 5-ACC GTT TTC CGC AGA GTT
CA. For the detection of endogenous Zbtb16, the sequence was
F 5-TGG CTG TGG CAA GAA GGT CA; R 5-AAC CAA
GGA GGG CAG AGA CC.
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Fig. S1. Immunoblot analysis showing PLZF expression levels in thymocytes (Upper) and CD4 T cells (Lower) isolated from transgenic animals of lines 1 and
2. Actin was used as loading control. The equivalent of 8 105 thymocytes and 1.5 106 CD4 T cells was loaded per lane. For WT CD4, T cells were sorted for
CD62L subsets. Histogram (Right) depicts GFP expression levels in transgenic thymocytes (Upper) and CD4 T cells (Lower) (Line 1, thick line; line 2, dotted line.)
The shaded area indicates a WT control. All data are representative of two independent experiments.
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Fig. S2. (A) Numbers of splenic CD3 (Left) and CD4 T cells (Middle), and of lymph node CD3 T cells (Right) in eitherWTmice or in animals of PLZF transgenic
lines 1 and 2. Each symbol represents onemouse. (B) Diagram shows the splenic CD4/CD8 T cell ratio ofWTmice, and of transgenic lines 1 and 2mice. Each symbol
represents one mouse. (C) The percentage of CD44hi cells in splenic CD4 and CD8 T cell subsets is WT and PLZF transgenic mice (lines 1 and 2) is shown
(n  4).
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Fig. S3. CD4 and CD8 expression pattern on LN CD3 T cells isolated from WT mice and from PLZF transgenic line 1 (Left). CD62L and CD44 expression pattern
on CD4 and CD8 gated T cells (Right). Numbers in the dot plots indicate the percentage of cells in the respective quadrant. Data are representative of at least
six independent experiments for each transgenic line.
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Fig. S4. (A) Statistical analysis of WT and PLZF transgenic (line 1) thymocytes. Diagrams show total thymocyte numbers (Left), the thymic CD4SP/CD8SP ratio
(second from left), and the percentage of DP, CD4SP, and CD8SP thymocytes (third, fourth, and ﬁfth panels, respectively). Each symbol represents one mouse.
(B and C) Summary showing IFN production of ex vivo PMA/ionomycin stimulated thymocytes (B) and splenocytes (C). Percentage of IFN-producing CD4SP and
CD8SP thymocytes (Upper) and percentage of IFN-producing cells within the CD44hi population of CD4SP and CD8SP cells (Lower). In C, splenocytes were gated
on CD4 or CD8 T cells. Results shown are the summary of three mice analyzed.
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Fig. S5. CD62L and CD44 expression on splenic CD4 and CD8 T cells isolated from 2-week-old WT and PLZF transgenic mice (line 1). Dot plot (Left) indicates
gating regions for CD4 and CD8 T cells. Data are representative of four mice.
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Fig. S6. CD122 expression in PLZF transgenic (line 1) CD4 (Upper) and CD8 (Lower) CD44loCD62L, CD44hiCD62L, and CD44hiCD62L T cell subsets. Numbers
below histograms indicate the percentage of cells in the indicated region. Data are representative of three mice.
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Fig. S7. (A) The percentage of GFP and GFP CD4 transgenic CD1d-tet NKT cells from the spleen is shown. The results are the summary of three mice
analyzed. (B) Statistical analysis of the thymicNKT cell defect inWTand PLZF transgenicmice (line 3). Diagrams indicate the percentage of stage 2 (CD44NK1.1)
and stage 3 (CD44NK1.1) CD1d-tetHSAlo NKT cells of all mice analyzed (n  3).
Raberger et al. www.pnas.org/cgi/content/short/0805733105 8 of 9
51
Fig. S8. Semiquantitative RT-PCR analysis shows Tbx21 (encoding for T-bet) and Gata3 expression in various peripheral CD4 T cell subsets. Hprt1 expression
was used as loading control. Data are representative of two different experiments (line 3). The following primers were used: Tbx21, F 5-TGCAGTGTGGAAAGG
CAG AA; R 5-GGG TAG AAA CGG CTG GGA AC; Gata3, F 5-CAA TGC CTG CGG ACT CTA CC; R 5-GTC AGC ATG TGG CTG GAG TG.
Raberger et al. www.pnas.org/cgi/content/short/0805733105 9 of 9
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3.3  The  protein  tyrosine  kinase  Tec  regulates  IL‐17‐producing 
memory‐like CD4+ T cells 
Summary 














cells express  three members of  the Tec kinase  family, Tec,  Itk and Rlk. A  large number of bio‐





tion  is  impaired  in the absence of  Itk, and  Itk–/– T cells were unable to polarize towards a Th2 






fect within the T cell  lineage 15. The analysis of  Itk–/–Rlk–/– T cells however showed that Rlk  is 
involved  in TCR‐mediated signaling events and that  it partially compensates  for the  loss of  Itk, 
indicated by  a  further diminished proliferative  response upon  anti‐CD3  stimulation  and  a de‐
crease  in  IL‐2 and IFN production  in  Itk–/–Rlk–/– T cells compared to  Itk–/– T cells 15. Further, 





normally  in  the absence of Tec. However,  the combined deletion of Tec and Btk  resulted  in a 
severe  impairment of B  lymphocyte development and  function  16,  indicating  that  in  the B cell 

























tion  in  the  ratio of naïve  (CD44loCD62L+)  to memory‐like  (CD44hiCD62L–) CD4+ and CD8+ T  cell 
subsets (Figure 1A and data not shown). Furthermore, CD4+CD25+ regulatory T cells are present 
at similar numbers in WT and Tec–/– mice (Figure 1B).   
To  test whether Tec  is  required  for efficient T cell proliferation, CD4+ T cells  from WT and 
Tec–/– mice were isolated and stimulated with various concentrations of plate‐bound anti‐CD3. 
There was no difference in the proliferative capacity of Tec–/– CD4+ T cells compared to WT CD4+ 
T cells  (Figure 1C). This correlated with a  similar up‐regulation of  the early activation markers 
CD25  and  CD69  (data  not  shown).  Several  studies  have  implicated  Tec  in  the  CD28  co‐
stimulatory pathway and  in the production of  IL‐2 18,21,22. However, proliferation  in response to 
anti‐CD28‐mediated  co‐stimulation  and  IL‐2  production was  similar  in  Tec–/–  and WT  CD4+  T 
cells  (Figure  1D).  This  is  in  agreement  with  previous  data  showing  a  normal  anti‐CD28  co‐
stimulatory response of Tec–/– CD3+ T cells 16. 
TCR crosslinking  leads to the tyrosine phosphorylation and activation of several proteins 23. 















3Hthymidine  incorporation during the  last 16 hours. Data are representative of 4  independen t experi‐
ments. (D) CD4+ T cells were stimulated for 60 hours with plate‐bound anti‐CD3 (0.3 µg/ml) ± plate‐bound 
anti‐CD28 (3 µg/ml) (left panel) or PMA (50 ng/ml) and  ionomycin (500 ng/ml) (middle panel). Prolifera‐
tion was assessed  in triplicates by 3Hthymidine  incorporation during the  last 16 hours. Right panel: Bar 































cells  (Figure  3A)  and  produced  also  higher  levels  of  IL‐17  (Figure  3B).  Next, we  investigated 
whether the increase in IL‐17 and the elevated expression of the Il23r in Tec–/– CD4+ T cells cor‐
related with increased STAT3 phosphorylation. In contrast to WT CD4+ T cells, which showed low 
























triangle  indicates 5‐fold dilutions of  input. Data are  representative of 2 different experiments.  (B)  IL‐17 
expression  levels  in the culture supernatant of activated CD4+ T cells that were used for the  isolation of 
mRNA as described in (A). (C) CD4+ T cells were activated as described in (A), and restimulated with IL‐23 
for the indicated time periods. The cell lysate equivalent of 1 x 106 CD4+ T cells was loaded on a 10 % SDS‐









presence of  TGFβ plus  IL‐6. We  found  that WT  and  Tec–/–  Th17  cells were  generated  at  the 
same frequency and produced similar  levels of  IL‐17  (Figure 4A and 4B),  indicating that Tec ki‐
nase  does  not  regulate  the  differentiation  of  Th17  cells.  Furthermore,  the  development  of 
FoxP3‐expressing regulatory T cells, generated from naïve CD4+ T cells  in the presence of TGFβ 
was not altered  in  the absence of Tec  (Figure4A). We also could not observe a difference be‐














for TGFβ +  IL‐6 and of  two  independent experiments  for TGFβ only.  (B) Sorted naïve CD4+ T cells were 
activated with antiCD3/CD28 as described  in  (A) and cultured for 5 days with TGFβ +  IL‐6. Purified pola‐







The observations that TGFβ plus  IL‐6‐generated Tec–/– Th17 cells produced WT  levels of  IL‐17, 
and that EAE induction is similar in WT and Tec–/– mice indicated that Tec does not play a major 














the production of  IL‐17  (Figure  5A), we wanted  to  analyze whether  the observed  increase  in 
STAT3 phosphorylation in total CD4+ T cells (as shown in Figure 3C) was due to increased pSTAT3 
in memory‐like CD4+ T cells. However, after activation (and the corresponding up‐regulation of 









pSTAT3  (Figure 5B,  left panel).  In  control cells  that have been  stimulated with  IL‐6, an almost 
complete and uniform shift of pSTAT3 could be detected both in naïve and memory‐like popula‐































with plate‐bound anti‐CD3  (1 µg/ml) plus plate‐bound anti‐CD28  (3 µg/ml). The cell  lysate equivalent of 
0.5 x 106   CD4+ T cells was  loaded on a 10 % SDS‐polyacrylamide gel and  the expression of Tec was as‐
sessed by immunoblot analysis. PLC1 was used as loading control. > indicates the Tec‐specific band, while 
“ * “  indicates a non‐specific background band. One  representative of  two  independent experiments  is 
shown. (B) Naïve and memory‐like CD4+ T cells of the indicated genotype were isolated and activated for 5 
days with plate‐bound anti‐CD3 (1 µg/ml) plus plate‐bound anti‐CD28 (3 µg/ml). 5 x 105 cells were resti‐
mulated with anti‐CD3 for 12 hours. The  IL‐17  levels  in the supernatant were determined by ELISA. One 
representative of two independent experiments is shown. (C) Summary showing IL‐4, IFNγ and IL‐17 level 
in memory‐like CD4+ T  cells as determined by ELISA. Cells were activated as described  in  (D). For each 
experiment, WT cytokine levels were set as one, and the diagram shows relative cytokine levels. The cyto‐










similar  (Figure 7A and 7B),  there was an  increase  in  the percentage of  IL‐17‐producing Tec–/– 
CD44hi CD4+ T cells compared  to WT CD44hi CD4+ T cells. This  indicates  that a  subset of  IL‐17‐
producing CD4+ T cells  is  increased within the memory‐like population  in Tec–/– mice with  im‐
mediate effector function.  
 









signaling  in naïve CD4+ T cells.   Further, the differentiation of naïve CD4+ T cells  into Th1, Th2, 
Th17  and  regulatory  T  cells was normal. However,  ex  vivo  PMA/ionomycin‐stimulated  Tec–/– 




IL‐17  and  showed  increased  STAT3  phosphorylation  upon  IL‐23  stimulation  compared  to WT 
cells. Thus, our data provide a detailed description of the function of Tec in CD4+ T cells and indi‐
cate a critical  role  for Tec  in signaling pathways  that  regulate a population of  IL‐17‐expressing 
memory‐like CD4+ T cells with immediate effector function. 
Effector CD4+ T  cells  can be  subdivided  into at  least  four main  subsets, namely Th1, Th2, 
Treg, and Th17 subsets, each having a specific function in the fight against different pathogens. 
We did not detect any alteration  in Tec–/– Th1 and Th2 cells with respect to IFN and IL‐4 pro‐





linked  to  the  increase  in  IL‐17. CD4+ T cells were activated  in  the presence of anti‐murine  IL‐2 
antibody with or without recombinant human IL‐2. Preliminary results showed that blocking IL‐2 
rather reduces IL‐17 secretion, while the addition of IL‐2 had no effect (data not shown), indicat‐




there was  no  difference  in  IL‐21  production  between WT  and  Tec–/–  CD4+  T  cells  (data  not 
shown). Thus Th17 differentiation appears to be normal in the absence of Tec. This may explain 








CD4+ T cells produced  IL‐17 under non‐polarizing conditions. This  suggested  that a population 






antigen  exposure. Rather,  this population  contains  in  addition  a  variety of  cell  subsets,  some 




an  increase  in memory‐phenotype CD4+ and CD8+ T cells, since  Itk  is essential for the develop‐
ment  of  conventional  (i.e.  non memory‐phenotype)  T  cells  53‐57.  The  observation  that  ex  vivo 
PMA/ionomycin‐stimulated Tec–/– CD44hi CD4+ T cells contained a higher percentage of an  IL‐
17‐producing population compared  to WT cells  further  indicated  that a memory‐phenotype or 
memory‐like population may be affected by the loss of Tec. The role of Tec seems to be specific 
for  an  IL‐17‐producing  T  cell  subset,  since  IFN‐producing  CD44hi  subsets  had  a  similar  abun‐
dance  in  Tec–/–  and WT  cells. Thus, our data indicate a critical role for Tec in signaling 
pathways that regulate the generation and function of an IL-17 producing memory-like 
CD4+ T cell subset. 











A potential mechanism by which Tec  regulates  IL‐17‐producing CD4+ T cells  is provided by 














cells were  co‐cultured with Tec‐deficient memory‐like T  cells.  In  future experiments  it will be 






















TC‐anti‐CD4  (CT‐CD4),  FITC‐  or  bio‐anti‐CD8  (5H10),  PE‐anti‐CD25  (PC61.5.3),  PE‐anti‐CD44 
(IM.7.8.1),  bio‐anti‐CD45R  (B220),  bio‐anti‐Ly‐6G  (RB6‐8C5),  bio‐anti‐erythroid  cells  (Ter119), 
and  bio‐anti‐NK1.1  (PK136).  The  Alexa  fluor  647‐anti‐mouse‐FoxP3  and  bio‐anti‐CD45.2  (104) 
were from eBioscience. Murine IL‐4 (mIL‐4) and mIL‐12 were from Peprotech and mIL‐6, mIL‐23 











CD4+ T Cells were grown  in RPMI  (Sigma),  supplemented with 10% FCS  (Gibco), antibiotics,  L‐
Glutamine and 2‐mercaptoethanol (Sigma).  
T cell proliferation assay 
















mers:  Hprt‐F:  5’‐ATTGTGGCCCTCTGTGTGCT,  Hprt‐R:  5’‐TTGCGCTCATCTTAGGCTTTG,  Il23r‐F:  5’‐ 
TTCTGCGTCCATCATTTCCA, Il23r‐R: 5’‐CCATTCCCGACAAAAGTCCA. 
Differentiation and activation of the various CD4+ T cell lineages 
Purified  CD4+  T  cells were  stimulated with  plate‐bound  anti‐CD3  (1  µg/ml)  and  plate‐bound 
anti‐CD28  (3 µg/ml) on 48 well plates  (0.5 to 1 x 106 cells/well). For non‐polarizing conditions, 
cells were activated in the presence of rhIL‐2 (20 U/ml). For Th1 polarizing conditions, cells were 








coated with or without  anti‐CD3  (1 µg/ml).  Supernatant  for  cytokine quantification was  col‐
lected 12 h  later. In some experiments, sorted naïve and memory‐like CD4+ T cell subsets from 
WT  and  Tec‐deficient mice were  co‐cultures  at  a  14:1  ratio  in  different  combinations  as  de‐

















Ly5.2+ WT  or  Tec–/–  CD44hiCD62L–  (memory‐like)  CD4+  T  cells,  and  Ly5.1+ WT  CD44loCD62L+ 
(naïve) CD4+ T cells were  isolated by sorting. Then, naive Ly5.1+ WT cells were co‐cultured with 
either WT or Tec–/– memory‐like cells at a ratio that exists in WT or Tec–/– mice (approx. 14:1). 
The mixed cell populations were stimulated  (under  the same conditions as  total CD4+ T cells), 
rested, starved  in RPMI/1% FCS and  reactivated at 107 cells/ml  in RPMI/1% FCS with  IL‐23  (10 
ng/ml) or  IL‐6  (10 ng/ml)  for 15 minutes. The  reaction was  stopped by addition of 16 % PFA, 
yielding a  final concentration of 2 % PFA. Cells were  left  for 20 minutes  in PFA and were  then 
permeabilized for 20 minutes with methanol at a final concentration of 80 %. Cells were washed 
twice with  PBS/2 %  FCS  and  stained with  FITC‐anti‐CD4,  biot‐anti‐Ly5.2  and  Alexa‐647‐  anti‐
phospho(Y705)STAT3.  Cells were washed,  incubated with  PE‐Cy7‐streptavidin.  Data were  ac‐
quired on a FACSCalibur (BD) and evaluated using FloJo (Treestar). 
Western blotting 
T cells were pelleted and  lyzed  in Carin  lysis buffer  (20 mM Tris‐HCl pH 8.0, 138 mM NaCl, 10 
mM  EDTA,  100 mM NaF,  1 % NP40,  10 % Glycerol,  2 mM NA‐Vanadate)  supplemented with 
complete protease inhibitors (Roche). Proteins were then separated on 10 % SDS‐polyacrylamide 
gels  and  blotted  onto  PVDF membranes.  The  anti‐phosphotyrosine  antibody  4G10 was  from 
Upstate. Anti‐PLC1  and  anti‐P‐STAT3  (Y701)  antibodies were  from  Cell  Signalling.  The  rabbit 
anti‐C‐terminal Tec was a kind gift of H. Mano, Jichi Medical School, Japan. Anti‐STAT3 was from 
Santa Cruz. Secondary antibodies were from Jackson Immunoresearch (West Grove, PA). 
For STAT3  immunoblots, cells were purified after 6 days  in culture over a  lymphoprep gra‐
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Abstract: A variety of different cell lineages of the hematopoietic system are activated during inflammatory processes. 
These cells not only contribute to the beneficial outcome of an immune response, but can also cause pathology such as 
autoimmunity as a consequence of extended or uncontrolled reactions. Therefore, an understanding of the basic mecha-
nisms that lead to immune cell activation and the identification of key molecular players will also lead to strategies to-
wards therapeutic manipulation of extended immune reactions. Members of the Tec kinase family (Bmx, Btk, Itk, Rlk and 
Tec) constitute an important class of non-receptor protein tyrosine kinases that are primarily expressed in the hema-
topoietic system. They are activated upon a variety of signals and are important participants of major signal transduction 
pathways in immunological processes. Hence, deficiencies in Tec family kinases cause several immunological defects, 
both in man and mice. Since Tec family kinases have been shown to function as modulators of immune cell activation, 
they may provide attractive drug targets for the manipulation of the immune response. In this review, we summarize re-
cent data from studies about the activities of Tec family kinases in inflammatory cells and their role in in vivo models of 
infection, inflammation and autoimmune diseases.  
Keywords: Tec family kinases, inflammation, mouse models, immunity, Th1/Th2. 
INTRODUCTION 
 The inflammatory response is a continuous sequence of a 
variety of different processes. After detection of infection or 
tissue damage, the inflammatory process begins with 
changes in tissue homeostasis and blood flow, and the migra-
tion of immune cells in waves comprised of different cell 
types to the site of pathogen exposure or tissue trauma. In a 
normal situation, the recruited inflammatory cells remove 
pathogens or cellular debris. Subsequently, the immune cells 
themselves are removed leading to the cessation of the in-
flammatory response. However, any alterations in the bal-
ance between the activities of the inflammatory cells can 
cause pathology, leading to diseases such as chronic inflam-
mation, asthma and arthritis [1]. 
 At a cellular level, various cells of the immune system 
participate in the inflammatory response. The local release of 
mediators such as cytokines and chemokines at the site of 
infection and injury leads to the recruitment and activation of 
neutrophils and subsequently macrophages, which them-
selves are then activated by the presence of cytokines or bac-
terial components such as LPS. This leads to the initiation of 
various signal transduction cascades within these cells and 
the subsequent activation of their microbicidal activities. The 
activation of non-receptor protein tyrosine kinases (PTK) is 
one of the first steps in the signal transduction cascades that 
lead to activation of immune cells upon binding of a ligand 
to its receptor. One class of non-receptor PTK that is acti-
vated by a variety of signals present at the inflammatory site 
are the Tec family kinases, which form the second largest  
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Tel: +43-1-40160-65003; Fax: +43-1-40160-965006;  
Email: wilfried.ellmeier@meduniwien.ac.at 
†These authors contributed equally 
family of non-receptor PTK in the hematopoietic system. 
Several recent reviews summarize the current knowledge 
about the structure, activation pathways and function of Tec 
family kinases in cells of the innate and adaptive immune 
system [2-4]. In this review we focus on the in vivo role of 
immune cells deficient for members of the Tec family kinase 
and summarize recent studies using mouse models for in-
flammatory diseases and autoimmunity. 
A BRIEF OVERVIEW ABOUT TEC FAMILY 
KINASES AND THEIR FUNCTIONS IN SIGNAL 
TRANSDUCTION CASCADES  
 The name giving member of this kinase family, Tec (ty-
rosine kinase expressed in hepatocellular carcinoma), was 
identified in 1990 [5]. In addition to Tec, four additional 
mammalian members of the Tec kinase family have been 
described: Bmx (Bone marrow kinase on the X chromosome; 
also named Etk) [6-8], Btk (Bruton’s tyrosine kinase) [9-11], 
Itk (IL-2-inducible T cell kinase; also known as Emt) [6, 12, 
13], and Rlk (Resting lymphocyte kinase; also designated 
Txk) [14, 15]. The expression of Tec family kinases is re-
stricted primarily to the hematopoietic system (for a review 
see [4]), although expression of Bmx and Tec has been de-
tected in endothelial cells [7] and liver [5], respectively. Tec 
family kinases came into the focus of immunological interest 
in 1993 when it was shown that a broad range of mutations 
in one member of this family, Btk, are the cause of X-linked 
agammaglobulinemia (XLA) in humans [10, 11]. XLA is an 
immunodeficiency characterized by a severe reduction of 
serum immunoglobulin (Ig) levels due to defects in B lym-
phocyte development and function. A similar although less 
severe syndrome in the mouse, X-linked immunodeficiency 
(xid), is caused by a point mutation in the btk gene [9]. The 
most characteristic feature of Tec family kinases (with the 
exception of Rlk; see below) is a pleckstrin homology (PH) 
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domain located at the N-terminus of the molecule (see Fig. 
(1)). The PH domain is followed by a short so-called Tec 
homology (TH) domain, and by the Src homology (SH) do-
mains SH3 and SH2, known to interact with proline-rich 
sequences or to bind to sequences containing phosphorylated 
tyrosines, respectively [16, 17]. In contrast to Src family 
kinases, Tec family kinases do not have a C-terminal nega-
tive regulatory tyrosine residue, indicating different regula-
tory modes. PH domains, found in a number of intracellular 
signaling molecules, are able to bind phospholipids or pro-
teins [18]. TH domains, consisting of a Btk homology (BH) 
motif and of one or two proline-rich (PR) regions, have been 
implicated in the auto-regulation of Tec kinases [19]. The 
TH and SH3 domains of Itk are able to interact intra-
molecularly, thus preventing the interaction of these domains 
with their prospective ligands. Furthermore, binding of the 
PR region of Tec family kinases to Src family kinases has 
been demonstrated [20]. Rlk represents an atypical Tec fam-
ily kinase member since it lacks the PH domain and the BH 
motif. Instead, Rlk contains an N-terminal palmitoylated 
cystein rich sequence that anchors Rlk to the membrane [21]. 
 Tec family kinases have been most extensively analyzed 
in the lymphoid lineages. A large number of biochemical, 
functional and genetic studies, in particular focusing on Itk 
and Btk, have shown that the activation of Tec family 
kinases upon antigen receptor stimulation requires several 
key regulatory steps (for detailed recent reviews on the acti-
vation of Tec family kinases and their role in T and B cells, 
see [2, 3]). These regulatory steps involve regulation by sub-
cellular localization, phosphorylation and colocalization with 
membrane associated adapter proteins and intra- and inter-
molecular interactions. In a first step of the activation of Tec 
family kinases, the molecule has to be localized to the 
plasma membrane, a process that is mediated by the interac-
tion of the PH domain with phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) generated by PI3-Kinase (PI3-K) activ-
ity. The interaction of the PH domain with PIP3 targets Tec 
family kinases to specific membrane microdomains (lipid 
rafts or glycolipid-enriched membrane microdomains, GEM) 
[22-25]. Rlk does not contain a PH domain, however Rlk can 
be anchored to the membrane via palmitoylation of a N-
terminal cysteine-string motif [21]. This leads to a constitu-
tive localization of Rlk to lipid rafts [26]. Upon localization 
of Tec family kinases to the membrane, a tyrosine residue 
within the activation loop of the kinase domain is phosphory-
lated by Src family kinases, which subsequently, upon auto-
phosphorylation of a tyrosine residue within the SH3 do-
main, results in the full activation of Tec kinases (see [2, 3] 
and references therein). In addition to translocation and 
phosphorylation, the activity of Tec family kinases is also 
regulated by their interaction with adaptor molecules such as 
SLP-76 and SLP-65 [27] and LAT (via Grb2 [19, 22]), lead-
ing to recruitment and integration of Tec family kinases into 
BCR- or TCR-initiated signaling pathways. As mentioned 
Fig. (1). Schematic map of Tec family kinases in comparison to Src family kinases. 
The hallmark of Tec family kinases is the PH domain at the N-terminus, shown to mediate protein-phospholipid and protein-protein interac-
tions. The TH domain, formed by the BH motif and the PR region(s), is involved in the autoregulation of Tec family kinases. The SH3 do-
main binds to proline-rich sequences, and the SH2 domain to phosphotyrosine residues. Although Rlk lacks the PH domain and the BH motif 
characteristic for Tec family kinases, the high sequence homology between the SH domains of Rlk and of other Tec family kinases classifies 
Rlk as member of the Tec kinase family. In contrast to Src kinases (SFK), Tec family kinases do not have a negative regulatory tyrosine resi-
due at the C-terminus. See text for further details. Abbreviations: BH, Btk homology motif; Cys, cysteine-rich sequence; N-Myr, N-terminal 
myristilation signal; PH, pleckstrin homology domain; PR, proline-rich region; SFK, Src family kinases; SH, src homology domain; TH, Tec 
homology domain. 
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above, the TH domain (i.e. the PR within the TH domain) 
and the SH3 domain of Itk are able to interact intra-
molecularly, thus preventing the binding of these domains to 
potential ligands [19] and adding another potential layer of 
regulation. Similar observations have also been made for Btk 
and Tec, although they form preferentially homodimers via 
reciprocal TH/SH3 domain-mediated intermolecular interac-
tions [2]. 
 Biochemical studies of either Btk–/– or xid mice, human 
B cells derived from XLA patients or Btk-deficient chicken 
DT40 B cells indicate that Btk is required for full tyrosine 
phosphorylation and activation of phospholipase C2. As a 
consequence, Btk-deficient B cells show a reduced intracel-
lular Ca2+ mobilization [28, 29]. Similar observations have 
been described in Itk-deficient and Itk/Rlk double-deficient 
T cells [30-32], and in mast cells lacking Btk [33]. Beside 
their role in Ca2+ mobilization, Tec family kinases have been 
implicated in the regulation of apoptosis, the reorganization 
of the actin cytoskeleton, integrin activation during the for-
mation of the immunological synapse, and cell adhesion and 
migration processes (for detailed reviews see [34, 35]). Fur-
thermore, Tec family kinases have been linked to the regula-
tion of gene expression, not only indirectly by causing a re-
duction of the activity of Ca2+-sensitive transcription factors 
of the NFAT family, but also due to their interaction with 
transcription factors such as Stat3 [36], Stat5 [37], BAP-
135/TFII-I [38] and bright [39]. Btk [39], Itk [40] and Rlk 
[21] can localize to the nucleus, which may connect them via 
interaction with transcriptional regulators directly to the 
regulation of transcriptional activation. In line with these 
findings, it has even been demonstrated that Rlk can act as a 
Th-1-specific transcription factor that participates in the 
regulation of IFN expression [41]. Finally, Itk has been im-
plicated in regulating the activity of the Th1 key regulatory 
factor T-bet. T-bet can interact with the Th2 master regulator 
GATA-3 and thereby interferes with GATA-3 activity lead-
ing to the repression of Th2 commitment. In order to interact 
with GATA-3, T-bet has to be tyrosine phosphorylated, and 
Itk mediates this phospohorylation. This indicates that Itk-
dependent phosphorylation can regulate the interaction of 
two opposing transcription factors [42]. 
NEUTROPHIL FUNCTIONS IN THE ABSENCE OF 
TEC FAMILY KINASES 
 Tec family kinases are not only critical components of 
antigen receptor signaling pathways in lymphocytes, but are 
also activated in cells of the myeloid lineage by a variety of 
receptor signaling pathways such as integrin activation, Fc 
receptors, G-protein-coupled receptors, Toll-like receptors 
(TLR), death receptors and cytokine receptors [4]. Among 
the cells of the myeloid cell lineages, neutrophils are key 
cellular components of the inflammatory process. They are 
among the first cells being recruited to the site of inflamma-
tion. One of the main tasks of recruited neutrophils is the 
removal of pathogens from the site of inflammation (for a 
review see [43]). They can be activated by bacterial compo-
nents (like LPS or formylated peptides), which induce a 
number of neutrophil functions such as migration, phagocy-
tosis and the production of microbicidal substances like reac-
tive oxygen metabolites. Activated neutrophils that do not 
encounter any pathogens release their microbicidal effector 
substances after a certain time [44]. This creates a toxic envi-
ronment destroying pathogens, but can also lead to the de-
struction of extracellular matrix molecules and tissue dam-
age. Furthermore, chemotactic signals generated by neutro-
phils attract monocytes and dendritic cells and influence 
macrophage differentiation towards a pro- or anti-
inflammatory state (see [43] and references therein).  
 So far only very few studies addressed the role of Tec 
family kinases in neutrophils. Human neutrophils express 
Bmx, Btk and Tec [45]. Stimulation with the chemotactic 
factor fMLP induces membrane translocation and phos-
phorylation of all three kinases [45]. Crosslinking of the re-
ceptor CD16b (FcIIIB) on human neutrophils leads to the 
phosphorylation and translocation of Tec to the plasma 
membrane [46]. Btk might also influence neutrophil devel-
opment at least under certain circumstances. XLA patients 
show an increased incidence of neutropenia in association 
with infection. This indicates that Btk, although not normally 
required for neutrophil production, might be required during 
inflammation and infection [47]. Further indications for a 
role of Btk in neutrophils came from experiments using Car-
ragenan-induced edema as a model of neutrophil-dependent 
acute inflammation [48]. In this inflammation model, xid
mice show reduced footpad edema and neutrophils from xid
mice show an impaired induction of reactive oxygen inter-
mediates (ROI) and nitric oxide (NO) compared to neutro-
phils from control mice [49]. Using the Btk inhibitor LFM-
A13 to block Btk activity [50], it has been shown in vitro 
that neutrophils have reduced tyrosine phosphorylation pat-
terns upon fMLP stimulation in the presence of the inhibitor 
[51]. LFM-A13 inhibits the adhesion and chemotaxis of neu-
trophils and the production of superoxide anion [51]. LFM-
A13 has been reported also to inhibit degranulation of neu-
trophils upon CD16b crosslinking [46]. However, since it 
has recently been shown that LFM-A13 is also a potent in-
hibitor of Jak2 [52] and of Tec [46], some additional studies 
using complementary approaches (such as RNAi) to inacti-
vate Btk and/or Tec in human neutrophils should be per-
formed to confirm the proposed role of Btk and/or Tec in 
neutrophils. 
THE ROLE OF TEC FAMILY KINASES IN MONO-
CYTES/MACROPHAGES AND DENDRITIC CELLS  
 Macrophages are large phagocytic mononuclear cells and 
an important cell type in the inflammatory response. They 
constitute an extremely heterogenous population distributed 
over the whole body and are derived from the same bone 
marrow precursors as dendritic cells and osteoclasts. Mono-
cytes, the precursor of tissue macrophages, reside in the 
bloodstream. A subset of monocytes, upon migration into 
tissues, differentiates into resident tissue macrophages [53], 
which together with other stromal cells are capable of initiat-
ing the early stages of an inflammatory response [54, 55]. 
Another subset of monocytes is recruited upon inflammation 
and matures into inflammatory macrophages [56]. Macro-
phages are involved in virtually all inflammatory processes 
from the detection of pathogens up to the resolution of in-
flammation and repair of tissue damage. They have a wide 
array of surface receptors to detect pathogens, examples 
include complement and Fc receptors and TLRs. Apart from 
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Table 1. Tec Family Kinase-Deficient Mice Tested in In Vivo Models for Infections, Inflammation and Autoimmunity 
Disease model / infection Genotype Results/phenotype and references 
Experimental autoimmune en-
cephalomyelitis (EAE) 
xid • Slower induction of EAE and clinically less severe [49, 73] 
Carragenan-induced edema xid • Reduced footpad edema due to impaired neutrophil function [49] 
Dextran-sodium sulphate induced 
colitis 
xid • No weight loss upon induction of colitis [49] 
Collagen-induced arthritis (CIA) xid  • resistant to the induction of CIA on a DBA1 background [72] 
Allergic asthma Itk–/– • Attenuated symptoms of allergic asthma, reduced eosinophila infiltration, reduced mucus produc-
tion [81, 107] 
• Impaired CD4+ T cell function and cytokine production [81, 107] 
• Reduced contractile response [111] 
• Impaired airway mast cell degranulation [81] 
Allergic asthma wildtype • Itk inhibitor BMS-509744 shows dose dependent reduction of lung inflammation [113] 
Allergic asthma Btk–/– • One study reports exaggerated airway inflammation [77], while another one reports no differences 
[81]  
Early and late phase passive cuta-
neous anaphylactic reaction 
Btk–/– 
xid 
• Reduced early and late phase reaction [33, 81] 
Infection with Setaria digitata xid • Delayed clearance of filarial infection due to poor nitrite oxide production in macrophages [68, 
119] 
Infection with Nippostrongylus 
brasiliensis
xid • Increased IgE response [79] 
Infection with Schistosoma man-
soni
xid • On a Balb/c background higher susceptibility to infection and higher amounts of IgE and IgG1 
antibodies [80] 
Infection with Trypanosoma cruzi xid • On a Balb/c background poor B cell responses, however mice can control parasitemia [120] 
Infection with Leishmania major xid • On a Balb/c background resistance to L. major [121] 
Infection with Toxoplasma gondii Itk–/– 
Itk–/–Rlk–/– 
• Graded defects on lethality upon infection, Itk–/–Rlk–/– mice are more severely affected than Itk–/–
mice [31] 




• Itk–/– mice have decrease Th2 response, however Itk–/–Rlk–/– mice display normal Th2 response 
[100] 
Infection with Leishmania major Itk–/– • On a Balb/c background development of a Th1 instead of a Th2 response and therefore mice are 
capable of clearing the intramacrophage parasite (unlike wildtype control mice) [99] 
Infection with lymphocytic 
choriomeningitis virus (LCMV), 
vaccinia virus (VV), and vesicular 
stomatitis virus (VSV) 
Itk–/– 
Itk–/–Rlk–/–
• Normal elimination of LCMV in Itk–/–, Itk–/–Rlk–/– and control mice [101, 102] 
• VV is cleared with delayed kinetics in Itk–/– mice [101] 
• Antibody responses to VSV infection are similar in Itk–/– and control mice [101] 
• Ex vivo CTL responses to LCMV are reduced in Itk–/– mice [101] 
• Reduced numbers of LCMV-specific CD8+ T cells in Itk–/– and Itk–/–Rlk–/– mice [102] 
• Impaired accumulation of CD8+ T cells in response to LCMV or VV infection in Itk–/– and Itk–/–
Rlk–/– mice [102] 
Table listing the various infection, inflammation and autoimmune disease models applied to Tec family kinase-deficient mice together with the observed phenotypes and the citations 
of the studies performing the experiments.
clearing infectious microorganisms, inflammatory macro-
phages can also initiate the destruction of extracellular ma-
trix and the death of stromal, parenchymal and other immune 
cells. However, they are also involved in the secretion and 
stabilization of new matrix molecules and wound healing 
[57].  
 Three members of the Tec kinase family, Btk, Tec and 
Bmx, have been shown to be expressed in macrophages [58-
60]. Functional analysis of macrophages and biochemical 
studies of signaling pathways activated in the above men-
tioned processes have shed light on the role of Tec family 
kinases in macrophages during inflammation. Fc receptor- 
and complement receptor-dependent phagocytosis and che-
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motaxis are impaired in monocytes derived from XLA pa-
tients [61]. Tec family kinases have also been implicated in 
TLR signaling (for a review see [62]). Btk interacts with the 
TIR region of TLR2, 4, 8 and 9 as well as the adaptor mole-
cules MyD88 and MyD88-adaptor-like protein (Mal) [63]. 
Btk also binds to IRAK-1 but not TRAF6, both important 
molecules of the TLR signalosome [63-65]. Furthermore Btk 
is activated by the TLR4-ligand LPS in the human pro-
monocytic cell line THP-1 and dominant-negative Btk abro-
gates LPS activation of NF-B in U973 cells and the murine 
monocytic cell line RAW264.7 [63]. Btk is also activated in 
mouse peritoneal macrophages during the zymosan- or 
Staphylococcus aureus-induced release of arachidonate, the 
precursor of leukotrienes and prostaglandins, which are early 
mediators of inflammation. In addition, arachidonate release 
can be reduced by LFM-A13, further suggesting a role for 
Btk in this process [66]. Tec family kinases are also impli-
cated in TLR-induced signaling pathways and the subsequent 
induction of effector functions like cytokine production. Xid
macrophages show impaired p65 phosphorylation and trans-
activation upon LPS stimulation, while IkB-degradation is 
normal [67]. Furthermore, xid macrophages exhibit an im-
paired secretion of the proinflammatory cytokines TNF and 
IL-1 after stimulation with LPS [68]. In humans, mono-
cytes from XLA patients have been shown to be impaired in 
the production of TNF and IL-1 upon stimulation of the 
TLR4 or TLR2 [69], although another study reports that Btk 
is not essential for early LPS signaling [70]. Overexpression 
of Btk in normal human monocytes leads to the stabilization 
of TNF mRNA and therefore to an increase in TNF pro-
duction [58, 69]. Interestingly, incubation of XLA mono-
cytes with M-CSF leads to an increase in the expression of 
Tec and restores their ability to produce TNF upon LPS 
stimulation [58]. This suggests a compensatory role for Tec, 
similar to the situation observed in murine B cells [71], 
which may also explain why XLA patients show normal 
innate immune responses [58].  
 Functional studies of macrophages from xid mice have 
shown that Btk is required for efficient effector function. Xid
macrophages produce less of the effector molecule nitric 
oxide after induction with various stimuli. Macrophages 
from xid mice are also incapable of producing efficient 
bursts of ROI [49]. The impaired production of effector 
molecules or of pro-inflammatory cytokines might explain 
the delayed clearance of microfilarial infections in vivo in xid
mice [68]. It has been shown that xid mice are less suscepti-
ble to autoimmune and inflammatory diseases [72, 73]. 
These defects have mostly been attributed to B cell defects, 
but could also indicate a defect in macrophage function. Re-
cently, xid mice have been tested in several models for in-
duced inflammatory disease [49]. The development of ex-
perimental autoimmune encephalomyelitis (EAE) shows 
slower induction and is clinically less severe in xid mice as 
compared to wildtype controls, even though xid mice exhibit 
a Th1 bias due to impaired macrophage antigen presenting 
function [49, 74]. A similar reduction of disease severity in 
xid mice was also observed in dextran sodium sulphate-
induced colitis and Carrageenan-induced acute edema, two 
inflammation models that are independent of the adaptive 
immune system. Taken together, the decreased severity of 
several in vivo inflammation models in xid mice can be at-
tributed to impaired myeloid cell function due to the absence 
of functional Btk.  
 Btk is not only involved in the activation of TLR induced 
inflammation but is also critical for the dampening of an 
inflammatory response. Mal is phosphorylated by Btk [75]
and this phosphorylation is crucial for its interaction with 
SOCS-1. This interaction results in the polyubiquitination of 
Mal and its degradation by the 26S proteosome [76]. In sple-
nocytes derived from xid mice, Mal is not degraded upon 
TLR4 triggering, which leads to increased Mal-dependent 
NFB transactivation and potentiates TLR signaling and the 
pro-inflammatory response [76]. 
 Another example of Btk as a negative regulator was 
demonstrated in bone marrow-derived dendritic cells 
(BMDC). Btk–/– BMDCs exhibit a more mature phenotype 
and have an enhanced in vitro and in vivo T cell stimulatory 
capacity [77]. Btk–/– BMDCs produce reduced levels of the 
immunosuppressive cytokine IL-10 compared to their wild-
type counterparts and show impaired phosphorylation of 
Stat3 after LPS stimulation. Since IL-10 has been shown to 
induce Stat3-phosphorylation [78], these studies suggest that 
IL-10 production and subsequent Stat3 activation is regu-
lated by Btk-dependent signaling pathways that negatively 
regulate the maturation and T cell stimulatory capacity of 
BMDCs [77]. Using an allergic airway inflammation model, 
it has been reported that Btk–/– mice have an increased IgE 
response, exaggerated airway inflammation and a general 
enhancement of Th1 and Th2 responses [77]. Furthermore, 
adoptive transfer of antigen loaded Btk–/– BMDCs leads to 
increased IgE levels in recipients as compared to the transfer 
of wildtype BMDCs [77], providing a potential explanation 
for the observation of high IgE responses in xid mice upon 
infection [79, 80]. However, another study did not observe 
increased airway inflammation in Btk–/– mice [81]. Possible 
explanations for these differences could be different immu-
nization protocols and/or different genetic backgrounds of 
the mice used for the studies. 
MAST CELLS 
 Mast cells are well-accepted key players in pathological 
processes such as allergic asthma or systemic anaphylaxis. 
These disorders are characterized by uncontrolled antigen 
dependent activation of mast cells via cross-linking of the 
high-affinity IgE receptor (FcRI). Activated mast cells can 
release a tremendous amount of mediators that if out of con-
trol can lead to severe damage or even destruction of the 
respective tissues. A large body of evidence demonstrates 
that beside the FcRI signalosome, mast cell activation can 
occur via alternative pathways and that mast cells also influ-
ence innate and adaptive immune responses [82]. Mast cells 
are also required for the full development of autoimmune 
diseases in models such as MOG-induced EAE or arthritis 
[83-86] and have been implicated in the development of in-
flammatory bowel disease [87]. Thus inhibition of mast cell 
effector functions may represent one attractive avenue to 
target these pathological processes. 
 Mast cells express four out of five Tec family members 
(Btk, Itk, Rlk and Tec) and Btk, Itk and Tec are activated 
upon FcRI ligation [88, 89]; (Schmidt and Ellmeier, unpub-
lished data). Studies with Btk-deficient mast cells (either 
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from Btk–/– or xid mice) demonstrated that loss of Btk activ-
ity results in impaired histamine secretion, a mild impair-
ment of total leukotriene synthesis and in a more severely 
impaired cytokine production/secretion in vitro [33, 90, 91]. 
In vivo, impaired mast cell functions of Btk–/– mice were 
demonstrated by passive cutaneous anaphylactic (PCA) reac-
tions using both an early and late PCA model. Early ex-
travasation of Evan´s blue dye is significantly reduced in a 
dose dependent manner and Btk-deficient mice fail to induce 
skin edema [33]. A role for Itk during mast cell activation 
has been reported recently. Using an OVA-induced acute 
phase plasma extravasation model, it was shown that Itk–/–
mice exhibit a more pronounced reduction in the response as 
compared to Btk-deficient and wildtype control mice [81]. In 
line with this finding, Itk–/– airway mast cells also show a 
more severely decreased degranulation response in compari-
son to Btk-deficient and wildtype airway mast cells [81]. The 
contribution of Tec to mast cell biology is currently under 
investigation (U.Schmidt & W.Ellmeier, manuscript in 
preparation). To our best knowledge, there exist no reports 
describing a function for Rlk in mast cells. 
T CELLS AND TEC FAMILY KINASES IN 
ADAPTIVE IMMUNE RESPONSES AND DURING 
INFLAMMATION 
 CD4+ T cells have been traditionally classified into Th1 
and Th2 cell lineages. Th1/Th2 helper cell differentiation is 
regulated by the cytokine environment and lineage specific 
transcription factors. The transcription factor T-bet is a mas-
ter regulator of Th1 cell differentiation, while GATA3 is 
important for Th2 cell development. Th1 cells produce IFN
and regulate cell-mediated immunity, whereas Th2 cells pro-
duce IL-4, IL-5 and IL-13 and mediate the humoral arm of 
the immune response and also allergic responses (for reviews 
see [92, 93]). Recent data indicate the existence of a third 
subset of T helper cells that mainly produces IL-17 [94, 95]. 
It has been proposed that these so-called Th17 cells have 
crucial roles in regulating tissue inflammation and the occur-
rence of disease in several animal models of autoimmunity 
(for review see [96, 97]). 
 Tec family kinases are critical components of TCR-
mediated signaling pathways and crucial regulators of Th1 
and Th2 cell differentiation pathways (for a review see [98]). 
Infection of Itk–/–Rlk–/– and Itk–/– mice with Toxoplasma 
gondii display graded resistance against the pathogen with 
Itk–/–Rlk–/– mice showing the most reduced survival rate 
followed by Itk–/– mice compared to wildtype controls, indi-
cating in vivo defects in T cell function [31]. It has been 
shown that Itk-deficient T cells are not able to produce effi-
cient amounts of IL-4 even if they are cultivated under Th2 
skewing conditions [99]. In vivo, Itk–/– mice on a Balb/c 
background do not, unlike wildtype Balb/c mice, develop a 
Th2 response upon infection with Leishmania major. In-
stead, they develop a Th1 response and can clear the infec-
tion of the intramacrophagal parasite [99]. In a different in-
fection model, Itk–/– mice also show a decreased Th2 re-
sponse when challenged with Schistosoma mansoni eggs. In 
contrast, Rlk–/–Itk–/– mice are able to mount a protective 
Th2 response upon challenge with Schistosoma mansoni
eggs [100]. The mechanism of the restoration of the Th2 
response in Rlk–/–Itk–/– mice is not clear, however several 
possibilities have been recently discussed [98].  
 A few studies have also tested whether Rlk–/–Itk–/– and 
Itk–/– mice are able to mount a protective response against 
viral infection [101, 102]. Itk–/– mice were infected either 
with lymphocytic choriomeningitis virus (LCMV), vaccinia 
virus (VV) or vesicular stomatitis virus (VSV) [101]. LCMV 
is eliminated by day 8 in both Itk–/– and control mice, while 
VV is cleared with delayed kinetics in Itk–/– mice. Antibody 
responses to VSV infection are similar in Itk–/– and control 
mice. However, ex vivo primary cytotoxic T-lymphocyte 
responses against LCMV, VV or VSV are reduced after in-
fection of Itk–/– mice, showing a reduction of CTL re-
sponses in the absence of Itk in contrast to antiviral B cell 
responses. Antiviral responses to LCMV have also been 
tested in Itk–/–Rlk–/– mice. Similar to Itk–/– mice, double-
deficient mice are also able to clear the virus, even though 
the accumulation of antigen-specific CD8+ T cells is reduced 
in both Itk–/– and Itk–/–Rlk–/– mice compared to wildtype 
controls [102]. 
 Since Itk-deficient mice have an impaired Th2 response, 
it has been tested whether Itk could be a potential target in 
the treatment of allergic asthma. Allergic asthma is charac-
terized by an increase of Th2 cells and Th2 type cytokines in 
the lung, increased mucus secretion and inflammation of the 
airways [103]. Transfer of antigen-specific Th2 cells or in-
troduction of IL-4 and IL-13 alone can lead to airway hyper-
responsiveness along with all the symptoms of allergic 
asthma [104, 105]. Blocking the activity of these cytokines, 
as also shown for IL-4 in humans, reduces the development 
of disease [104, 106]. In an animal model for allergic 
asthma, Itk–/– mice exhibit attenuated immunological symp-
toms. Itk–/– mice display reduced eosinophil infiltration into 
the lung, show a reduced thickening of the epithelial cell 
layer lining the bronchioles, and also have reduced mucus 
secretion after induction of allergic asthma [81, 107]. Mice 
lacking Itk also show reduced antigen-specific recruitment of 
T cells into the lung and a diminished secretion of IL-4, IL-5 
and IL-13 by Itk-deficient T cells [107]. The reason for the 
reduced T cell infiltration is not clear, however multiple fac-
tors could contribute to the defects. Since chemokines are 
required for the recruitment of T cells into the lung in this 
model system [108], it has been speculated that the reduced 
T cell numbers might be due to altered chemokine/ 
chemokine-receptor signaling in Itk–/– T cells leading to 
impaired migration [109, 110]. Furthermore, adhesion de-
fects of Itk–/– T cells could contribute to the reduced num-
bers of T cells in the lung [25]. More recent observations 
show that isolated trachea from Itk-deficient mice have a 
reduced contractile response to stimulation with cholinergic 
agonists and depolarizing agents [111]. Since Itk is not ex-
pressed in trachea and smooth muscle, it has been suggested 
that the reduced contractile response in Itk-deficient mice 
could be due to the different local trachea cytokine milieu. 
One of the involved cytokines could be IL-13, which is 
known to affect contractile responses of smooth muscle cells 
[112], since reduced IL-13 mRNA levels are observed in the 
lungs of Itk-deficient mice [111]. In addition, the disease can 
be induced in Itk–/– mice by adoptively transferring antigen-
specific wildtype CD4+ T cells, thus confirming the major 
role of T cells in the development of allergic asthma [111]. 
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Finally, the Itk Inhibitor BMS-509744 has already been 
evaluated successfully in a murine allergic asthma model. 
This inhibitor is able to reduce lung inflammation in a dose 
dependent manner leading to a reduction of both total cell 
and eosinophil infiltration into the lung [113], thus support-
ing the concept that Tec family kinases are suitable targets 
for therapeutic intervention in inflammatory diseases. 
SMALL MOLECULE INHIBITORS FOR KINASE-
DEPENDENT AND KINASE-INDEPENDENT ACTIVI-
TIES OF TEC FAMILY KINASES 
 As mentioned above, inhibitors of Tec family kinases 
have been already identified. These inhibitors are directed 
against the kinase domain and can successfully impair its 
activity. However, kinase-independent functions for Btk and 
Itk have been reported as well. Kinase-dead Btk mutants can 
partially rescue the B cell developmental defects of Btk–/–
mice [114] and the tumor suppressor function of Btk in the 
absence of SLP-65 is also independent of its kinase activity 
[115]. Kinase-dead Btk is also capable of stimulating Cal-
cium influx in B cells upon BCR stimulation [116]. Further-
more, kinase-dead Itk can rescue TCR-induced Vav localiza-
tion and actin polarization in Itk-deficient T cells [117], and 
a mutant form of Itk that lacks the kinase domain can par-
tially rescue antigen receptor signalling in Btk–/– DT-40 
cells [118]. Taken together, these data indicate kinase-
independent functions and suggest that Tec family kinases 
may also act as adaptor and scaffolding molecules. There-
fore, optimal strategies using small molecule inhibitors to 
inactivate Tec family kinases should not only be directed 
against the catalytic domain but should also take into account 
the potential adaptor/scaffolding function of Tec family 
kinases.  
SUMMARY
 A large number of studies performed during the last dec-
ade have convincingly indicated that Tec family kinases 
have a crucial role in cells of both the innate and adaptive 
branch of the immune system and therefore also in inflam-
matory processes. Tec family kinases are activated by a vari-
ety of extracellular signals and are involved in cellular func-
tions essential to inflammation, such as differentiation, acti-
vation, adhesion, death and migration. Lymphoid and mye-
loid cell lineages express multiple members of Tec family 
kinases and genetic experiments have shown both unique 
and compensatory functions among Tec family kinases. In 
the near future combinatorial Tec family kinase knockout 
mice can be expected to provide a clear picture of the func-
tions of these kinases in the hematopoietic system, in immu-
nological processes in general and during inflammation in 
particular. Finally, some studies to determine whether and 
how Tec family kinase deficiency affects the outcome of 
experimentally-induced models for inflammation and auto-
immune diseases have already been performed and indicate 
that Tec family kinases are indeed promising targets for the 
treatment of inflammatory diseases. Thus, a better and 
broader understanding of the in vivo response of various Tec 
family kinase-deficient mice in several disease models will 
help to select particular members of Tec family kinases as 
candidates for rational drug design. 
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4.1 Potential crosstalks of the Tec kinase Itk with the TCR signal-
ing molecules Vav1 and Cbl-b 
TCR/CD28 triggering by antigen presenting cells induces a signaling cascade that leads to the 
activation of signaling molecules, the reorganization of the actin cytoskeleton and the formation 
of the so-called immunological synapse at the T cell/APC interphase. Together this leads to the 
activation of downstream signaling components and activation of transcription factors resulting 
in the induction of IL-2 expression, proliferation of the T cells and the generation of activated 
effector T cell populations, which is important for the development of a proper adaptive im-
mune response (1, 2). Existing crosstalks between the guanine nucleotide exchange factor Vav1 
and the Tec kinase Itk and the similar phenotype of Vav1–/– - and Itk–/– T cells suggest that these 
two proteins act in the same signaling pathways and at least partially perform similar functions 
in activated T cells. During my PHD study I further investigated potential interdependences and 
similarities between Itk and Vav1. 
To investigate whether the defects in peripheral Vav1–/– and Itk–/– T cells are mechanistically 
similar, we tested whether the defect of Itk–/– T cells is rescued upon deletion of the E3 ubiquitin 
ligase Cbl-b, as described for Vav1–/– T cells (3). The analysis of Itk–/–Cbl-b–/– mice revealed partial-
ly restored T cell function if Itk–/– T cells are released from the negative regulation mediated by 
Cbl-b. Thus, our data provide additional evidence that Vav1 and Itk fulfill similar functions in 
peripheral T cells. In addition, we wanted to address genetically whether there is functional re-
dundancy between Vav1 and Itk during T cell activation by generating Vav1/Itk double-deficient 
mice. The analysis of Vav1–/–Itk–/– mice showed severely reduced numbers of peripheral T cells, 
most likely as a consequence of diminished numbers of DP cells. Vav1–/–Itk–/– deficient DP cells 
showed a reduced life span in vivo compared to WT and single knock out DP cells, indicating that 
the combined activity of Itk and Vav1 is necessary for the survival of DP cells. The deletion of 
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Vav1 and Itk together could alter intracellular signaling pathways that are required for the sur-
vival of DP cells. Whether this survival signals are transmitted via cytokine receptors or via the T 
cell receptor or both still has to be determined. Preliminary data have shown that a kinase-dead 
version of Itk was able to rescue the survival defect of DP cells in a bone marrow reconstitution 
experiment, suggesting a scaffolding function for Itk for the survival of DP cells.  
The severely reduced numbers of peripheral T cells most likely are a consequence of the re-
duced numbers of DP cells in Vav1–/–Itk–/– mice. However, the remaining Vav1–/–Itk–/– deficient 
DP cells showed also a defect in positive selection, suggested by a further reduction of Ca2+ re-
sponse in DP cells and the absence of CD69+ single positive thymocytes. The already mentioned 
bone marrow reconstitution experiment showed that the kinase-dead Itk was not able to rescue 
the positive selection defect in Vav1–/–Itk–/– mice, showing the importance of the kinase function 
during positive selection, suggesting differential functional activity of Itk during T cell develop-
ment (illustrated in Fig. 1). 
Thus our data indicate an essential role for the combined activity of Vav1 and Itk for the sur-
vival of DP thymocytes and positive selection during T cell development. 
 
Fig. 1 is illustrating the differential functional activity of the Tec kinase Itk during T cells development to-
gether with the guanine nucleotide exchange factor Vav1. 
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4.2 The transcription factor PLZF and the development and func-
tion of memory phenotype T cells 
The CD44hiCD62L– memory T cell population consists not only of “true” antigen-specific 
memory cells that developed in response to a foreign antigen, but includes as well a variety of 
additional T lymphocyte subsets. These additional cells were described as memory-phenotype 
(MP) T lymphocytes, and some subsets of them also as innate-like T cells. MP innate-like T cells 
such as NKT cells, CD8αα IELs or others may play an important role in the front-line defense 
against certain bacterial infections. NKT cells have also been implicated in regulating autoim-
munity and inflammatory diseases, and they have been linked to the immune responses against 
tumors. Thus, MP innate-like T cells have important immune regulatory functions. 
The observations that PLZF is up-regulated in the Itk–/– T cell population (which is enriched 
in innate-like T cells), and that PLZF expression is restricted to the CD4+CD44hi population re-
vealed a correlation between PLZF expression and MP CD4+ T cells. During my PHD thesis I 
wanted to further address a potential role of PLZF in the development and function of memory 
phenotype T cells by generating T cell specific PLZF transgenic mice. Enforced expression of PLZF 
during T cell development and in peripheral T cells led to the appearance of a large population of 
peripheral T cells with a CD44hi memory-phenotype that were able to produce IFNγ upon ex vivo 
PMA/ionomycin stimulation. PLZF expressing (GFP+) T cells in female mice of line #3 (a line with 
a X-chromosomal integration site, resulting in mosaic expressing females) showed a MP but also 
similar numbers of GFP– T cells with a naïve phenotype, indicating a T cell intrinsic defect. In ad-
dition, the changes in the naïve versus memory-like subset distribution were already present at 
the SP stage during T cell development, revealing that the MP T cell populations in PLZF trans-
genic mice are at least in part derived from DP thymocytes, like other MP T cells (4, 5). Moreo-
ver, upon anti-CD3/CD28 activation we observed reduced cytokine production in all subsets of 
PLZF transgenic CD4+ T cells compared to WT CD4+ T cell subsets, except for the dramatic in-
crease of IL-4 production in the CD44hiCD62L+ subset. PLZF expression possibly could lead to a 
different cellular composition of peripheral CD4+ T cells, even though we could not observe any 
altered expression of T-bet and Gata-3 in the various subsets of PLZF transgenic mice compared 
to WT mice. These data revealed an important function of PLZF in the development and/or 
maintenance of memory phenotype T cells. 
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 Fig. 2 shows a hypothetic model of PLZF function during T cell development, and a potential role in the 
regulation of conventional verus non conventional T cell development. In the wildtype situation just very 
few innate-like T cells develop from a DP progenitor cell (upper panel), but if PLZF expression is enforced 
in DP and single positive cells, it shifts the balance from a naïve conventional T cell development into the 
development of either conventional T cells with effector function (scenario 1) or into innate-like T cells 
(scenario 2). 
Two recent studies have shown that PLZF is primarily expressed in CD1d-restricted NKT cells 
(6, 7). However, other MP T cell subsets may express also PLZF since PLZF expression was upre-
gulated in Itk–/– T cells which have diminished numbers of NKT cell subsets compared to WT T 
cells (8, 9). Interestingly, NKT cell numbers in mice lacking PLZF were severely reduced and they 
displayed also impaired characteristics usually associated with NKT cells (6, 7). Unexpected to 
this essential role of PLZF for NKT cell development and function, we observed a severe reduc-
tion of NKT cells in PLZF expressing mice compared to WT mice. One explanation that both PLZF-
deficient and PLZF transgenic mice have diminished numbers of NKT cells may come from the 
observation that stage 1 and stage 2 NKT cells express the highest level of PLZF and down-
regulate PLZF expression at stage 3 (6, 7). Therefore maintained transgenic expression of PLZF 
during NKT cell development may partially block NKT cells at this stage.  
The already mentioned studies by Kovalovsky et.al. and Savage et.al. demonstrate clear evi-
dence, that PLZF has a unique function in the development of NKT cells and their acquisition of 
“innate-like” characteristics. In addition our study indicates a more general role for PLZF in deci-
sions made during T cell development between conventional versus innate T cell lineages. In the 
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transgenic mouse model we could observe the appearance of a large population of CD44hi mem-
ory phenotype (MP) T cells beside the NKT cell lineage. So far not much is known about these 
additional MP T cell lineages. Recent findings from our laboratory are further strengthening the 
hypothesis that PLZF could be implicated also in the development or function of non-NKT- CD44hi 
T cells. Semi-quantitative RT-PCR experiments in wildtype T cell subsets revealed, that in addi-
tion to NKT cells PLZF is expressed also in other CD44hi CD4+ T cell subsets (unpublished data, J.R. 
and W.E.). The identity of these additional MP T cells still remains to be determined.  
There are at least two possibilities to explain the appearance of CD44hi T cells in PLZF trans-
genic mice. PLZF could convert conventional T cells into effector T cells, or PLZF could be part of 
a transcription factor network that induces a genetic program that leads to the differentiation of 
CD44hi innate-like MP T cells (Fig.2). Although we cannot formally exclude the former possibility, 
some observations argue in favor for the possibility that PLZF (in part) induces an innate-like T 
cell program. We observed changes in the CD62L expression pattern already in the thymus in 
CD4SP cells, in agreement with a published study (7). Furthermore, CD8SP cells have already a 
characteristic innate-like CD44hiCD62Llo expression pattern. This indicates that SP thymocytes are 
already altered, suggesting developmental changes. Furthermore, ectopic expression of PLZF 
leads to an increase of CD44hiCD62L+ and CD44hiCD62L– T cell subsets that in WT cells express 
PLZF, suggesting that PLZF can convert CD4+CD44lo subsets into CD4+CD44hi populations and that 
there is a link between PLZF expression and CD44hi cells. In contrast, reactivated Th1/Th2 cells 
generated from naïve (CD44loCD62L+) CD4+ T cells did not express detectable levels of PLZF (pre-
liminary data not shown), indicating that effector differentiation is not linked with PLZF expres-
sion. We further demonstrated that CD4+ and CD8+ MP T cells in PLZF mice possess in part in-
nate-like characteristics. The increase in IFNγ-producing transgenic CD44hi CD8+ T cells is similar 
to the one observed in innate-like Itk–/– CD8+ T cells, although the percentage of IFNγ-positive 
cells within the CD44hi population is higher in the absence of Itk. However, only peripheral MP 
CD8+ T cells and not CD8SP MP thymocytes in PLZF transgenic mice showed an increase in IFNγ-
producing CD44hi cells upon PMA/ionomycin stimulation, potentially suggesting peripheral ma-
turation processes of innate-like functions in CD8+ PLZF transgenic T cells. In contrast, IFNγ-
producing CD44hi cells were increased in the thymus and in the periphery in Itk–/– mice. Thus, 
only certain features are shared between PLZF transgenic T cells and the innate-like T cell sub-
sets described in Itk–/– mice. It is not known whether innate-like Itk–/– T cell populations have 
the same subset composition as WT innate-like T cell populations, and whether they function in 
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the same way like wt innate-like T cells. Therefore, differences between innate-like T cells from 
Itk–/– and PLZF transgenic mice may not be surprising. 
To determine whether, and if so how PLZF could regulate the decision between innate and 
conventional T cells further studies are required. One interesting question could address the 
timing of PLZF expression during T cell development. It would be interesting to determine 
whether PLZF has to be expressed at a certain developmental stage (e.g. during positive selec-
tion) or whether there is a developmental window at which PLZF expression is required to in-
duce the appearance of memory phenotype T cells. Furthermore it would be interesting to iden-
tify the signals and factors which induce the expression of PLZF. An additional interesting ap-
proach would be the identification of PLZF target genes by e.g. using Chip on ChIP technologies. 
There are still many open questions to be addressed concerning PLZF and its possible role 
during memory phenotype T cell development and function. The answers will give important 
insight into the development and function of non conventional T cells and therefore provide a 
better understanding of the first line of the adaptive immune system in the fight against an in-
fection. 
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